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Asthma may affect 
as many as 
334 million people.*
*For explanation see Chapter 2 “How many people have asthma?”
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Foreword
The Global Asthma Report 2014 has been prepared by the Global Asthma Network (GAN) Steering Group and invited 
authors with additional expertise. It provides substantial up-to-date information about asthma: each chapter is a state-
of-the-art summary of what is known and where the gaps lie, and each makes recommendations to authorities on 
required actions. Included are findings from new GAN surveys on asthma guidelines, national asthma strategies and 
access to quality-assured, affordable asthma medicines.
Designed for government ministers, policy-makers, health authorities, health professionals, patient support 
organisations and people living with asthma, this report gives an update of what is known about the global burden of 
asthma, management of asthma and capacity building, and ways of making asthma a global priority. 
It is encouraging to see that recognition of asthma as a global problem has increased since the first Global Asthma 
Report 2011 was published by the International Union Against Tuberculosis and Lung Disease (The Union) and 
International Study of Asthma and Allergies in Childhood (ISAAC).
GAN was established in 2012, building on the work pioneered and achieved by the ISAAC programme over the preceding 
20 years and the asthma management work of The Union in low- and middle-income countries. The people involved in 
founding GAN, from each organisation, were largely those involved in publishing the Global Asthma Report 2011. 
GAN is a worldwide collaboration, involving more than half the world’s countries. It will undertake global surveys of 
asthma in children and adults to measure and monitor asthma and its burden, providing the essential data called for 
by the World Health Organization. No one else is currently doing this work. GAN aims to reduce asthma suffering by 
improving asthma care globally, with a focus on low-and middle-income countries, achieving this through research, 
capacity building, and access to effective asthma management and care including quality–assured essential asthma 
medicines. 
Elsewhere, there have been other developments increasing the visibility of asthma. On 19 September 2011, the General 
Assembly of the United Nations (UN) made a political declaration on the prevention and control of non-communicable 
diseases (NCDs), focussing world attention on the increasing threat of asthma and other NCDs to global health, social 
welfare and economic development, especially in low- and middle-income countries. This was followed in 2013 by two 
reports from the World Health Organization (WHO) on NCDs: A Global Action Plan 2013-2020 and Global Monitoring 
Framework. In July 2014 the UN held a review meeting. In his opening address the UN Secretary General, Ban Ki-moon, 
said 
“…The global epidemic of NCDs is a major and growing challenge to development.  Each year, in developing countries 
alone, strokes, heart attacks, cancer, diabetes or asthma kill more than 12 million people between the ages of 30 and 
70…”.
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While estimating the number of people in the world with asthma 
remains difficult due to the many gaps in the data, the Global 
Burden of Diseases Study (GBD) published in 2012 gave us the 
latest estimate of asthma prevalence, indicating that as many as 
334 million people in the world have asthma, and that the related 
burden is high. 
Since 2012, WHO has published guidelines for the prevention and 
control of asthma in primary health care in low-resource settings. 
Guidelines on asthma from other organisations, including the Global 
Initiative on Asthma (GINA), have been updated. The European 
Academy of Allergy and Clinical Immunology (EAACI) has published 
a Global Atlas of Asthma. The Forum of International Respiratory 
Societies (FIRS) has published its report “Respiratory diseases in 
the world. Realities of today – opportunities for tomorrow”, which 
highlights asthma as one of the top 5 respiratory diseases in the 
world.
All these activities, concerns, developments and knowledge 
inform contents of the Global Asthma Report 2014 and its 
recommendations. We hope you will find it useful. We will continue 
to work together to increase the worldwide understanding of this 
disease, and to reduce the burden and suffering from asthma, over 
the next few years.
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Innes Asher
Chair
The Global Asthma Network
With good long-term management, the burden of asthma can be reduced. 
In the Global Asthma Report 2014, the Global Asthma Network (GAN) has brought together an up-to-date overview of 
the key issues regarding asthma globally.
When examining the burden of asthma today, there is much to be concerned about. 
Asthma is a common chronic non-communicable disease that affects as many as 334 million people of all ages in all 
parts of the world. It is a cause of substantial burden to people, often causing a reduced quality of life, not only due to 
its physical effects, but also its psychological and social effects. The various estimates of its economic burden, mostly 
due to productivity loss, are all significant. Further, avoidable asthma deaths are still occurring due to inappropriate 
management of asthma, including over-reliance on reliever medication rather than preventer medication. Asthma is a 
particularly serious burden in low- and middle-income countries least able to afford the costs.
While our knowledge has increased, the remaining gaps in the data are significant. 
While hospital admissions save lives during acute asthma attacks, there are many places where the number of hospital 
admissions is too high, and the reasons for this need more research. The factors affecting asthma also require further 
research.  New surveys are needed to update asthma trends, assess the burden of asthma and access to effective 
management. Meanwhile, GAN is working towards closing the data gaps. 
But much of this burden of disease and lack of information is avoidable.
Asthma which is well controlled imposes far less of an economic and personal burden than non-controlled asthma. 
Strategies towards improving access and adherence to evidence-based therapies can therefore be effective in reducing 
the personal and economic burden of asthma in all countries.  Implementation of relatively simple measures within a 
systematic national or local strategy can improve early detection of asthma and provide effective preventive treatment. 
Asthma management guidelines are an essential part of successfully managing asthma and promoting the delivery of 
quality asthma care; these are widely available. 
Political commitment and action are required to make the burden of asthma a thing of the 
past.
The Global Asthma Report 2014 makes many recommendations to the World Health Organization (WHO), governments, 
health authorities and health professionals, which, if followed, will transform asthma globally from a burden to an 
inconvenience.
Executive Summary
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As part of their asthma strategy, every country needs:
• An up-to-date approach to the diagnosis and management 
of wheezing in young children. This is an evolving field. This 
report includes a review of recurrent wheezing in infants including 
information from a recent international study. If an infant presents 
with frequent and/or severe episodes of recurrent wheezing they 
should be diagnosed and managed as asthma, unless there is 
evidence to the contrary. 
• Guaranteed access to quality-assured essential asthma 
medicines. This is vital to improving asthma outcomes. Essential 
asthma medicines need to be on all national lists of essential 
medicines and reimbursed medicines; this is not yet the case. 
Essential asthma medicines are inhalers which are complex devices, 
requiring accurate manufacturing to produce a reliable dose 
with particles of an inhalable size.  Many devices on the market 
are substandard or unaffordable. WHO has a key role in setting 
standards for these medicines, and all parties must working to make 
them affordable.  
• Effective policy action on known, remediable causes of asthma 
such as parental smoking (for children) and occupational exposures 
(for adults).
• Capacity building of trained health professionals. This is vital 
and can be enabled by participation in research.  Short courses 
in research generally, or asthma research in particular, provide 
opportunities for ‘upskilling’ in research for those with limited time 
and resources.
In low- and middle-income countries, efforts should be accelerated to 
make asthma a lung health priority. Asthma management and control 
is feasible even in low-income countries, and it should be on everyone’s 
agenda. In 2012 WHO published guidelines for asthma management in 
low-income settings.  
GAN will work with others to achieve better asthma outcomes through 
undertaking global surveys of asthma in children and adults, research, 
capacity building, improving access to effective asthma management 
and care, including quality-assured essential medicines, and through 
advocacy activities. 
Together, we can ensure that asthma is managed so that its associated 
disability, death, and economic drain is massively reduced – even if 
prevalence rises.
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The World Health Organization (WHO) should
• add essential asthma medicines to their Prequalification 
Programme, promote the standardisation of the dosages 
of active ingredients in combined inhalers and the 
harmonisation of quality requirements for inhalers 
across international reference documents such as the 
pharmacopoeias. 
Governments should 
• commit to research, intervention, and monitoring 
to reduce the burden of asthma in the world. Global 
surveillance of asthma requires standardised measures 
of asthma implemented in large scale surveys of both 
children and adults in diverse settings worldwide;
• include asthma in all their actions arising from the WHO 
Global Action Plan for the Prevention and Control of 
Non-communicable Diseases (NCDs) 2013-2020, and the 
WHO NCD Global Monitoring Framework;
• ensure that they have a list of essential medicines for 
asthma which includes both inhaled corticosteroids and 
bronchodilator in dosages recommended by WHO, and 
that these are available, quality-assured, and affordable 
for everyone in their countries;
• ensure all asthma inhalers procured, distributed and sold 
in their countries meet international quality standards;
• particularly in low-income countries, make 
commitments to ensure that the supply of quality-
assured, affordable essential asthma medicines is 
uninterrupted, health professionals are appropriately 
trained, and health services are organised to manage 
asthma;
Key Recommendations
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• particularly in low- and middle-income countries make asthma a 
health priority, in order to more quickly invest in asthma research 
relevant to their populations, integrate care at community and 
primary health care levels with appropriate referral procedures, 
and develop capacity in standard case management of asthma;
• strengthen policies to reduce tobacco consumption, encourage 
healthy eating and reduce exposure to potentially harmful 
chemicals, smoke and dust. Funders need to support further 
research to identify causes of asthma;
• measure and monitor the economic costs of asthma in their 
countries, including health care costs and productivity losses.
Health authorities in all countries should
• develop national strategies and action plans to improve asthma 
management and reduce costs;
• ensure the availability of nationally approriate asthma 
management guidelines and provide access for everyone to the 
quality-assured, affordable essential asthma medicines those 
guidelines recommend;
• encourage their health professionals to attend short courses 
relevant to asthma research and policy;
• collect counts of hospital admissions in children and adults, from 
defined catchment populations, to monitor trends in asthma over 
time;
• report rates of asthma deaths in children and adults to monitor 
progress in asthma care and as an early warning of epidemics of 
fatal asthma.
Health professionals in all countries should 
• regard frequent or severe recurrent wheezing in infancy as part of 
the spectrum of asthma;
• ensure that their country is represented in the Global Asthma 
Network (GAN).
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“A world where no-one 
suffers from asthma”
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THE GLOBAL 
ASTHMA  
NETWORK
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Global Asthma 
Network  
The Global Asthma Network 
(GAN) has grown out of the 
International Study of Asthma 
and Allergies in Childhood 
(ISAAC) and the International 
Union Against Tuberculosis and 
Lung Disease (The Union). It aims 
to reduce asthma suffering by 
improving asthma care globally 
with a focus on low- and middle-
income countries.  GAN will 
achieve this through undertaking 
global surveys of asthma in 
children and adults, research, 
capacity building, improving 
access to effective asthma 
management and care, including 
quality-assured essential 
medicines, and through regular 
advocacy activities. 
GAN plays a crucial role in collecting 
asthma data on adults and children globally; 
this data is not being obtained by any other 
group. In 2012 the leader of the World Health 
Organization (WHO), Dr Margaret Chan, said
 “Accurate assessment of the global, 
regional and country health situation and 
trends is critical for evidence-based decision 
making in public health…. The real need is 
to close the data gaps, especially in low-and 
middle-income countries”.  
For asthma this is exactly what GAN is 
doing – closing the data gaps.
GAN was established in 2012 to 
improve asthma care globally (www.
globalasthmanetwork.org). GAN is a new 
collaboration between individuals from 
ISAAC - isaac.auckland.ac.nz/ (now wound 
up) and The Union  - www.theunion.org. 
GAN is building on the work achieved 
by the ISAAC programme (1991-2012), 
which has an impressive track record of 
undertaking surveys which have contributed 
extensive data on asthma and allergies in 
children, monitoring these diseases over 
time, and researching possible causes. GAN 
is operating on the same principles used 
in ISAAC of collaborative and systematic 
application of standardised methodologies 
able to be used in all settings in the world. 
In addition to asthma in children, GAN will 
study asthma in adults. Surveys will be 
conducted and repeated as resources allow.
GAN is led by an 11-member international 
Steering Group responsible for developing 
and overseeing its work programme. Long-
term targets have been developed (Figure 1). 
The GAN Data Centre is located in Auckland, 
New Zealand. The Data Centre leads the 
surveys, communicates methodologies, 
1. Innes Asher, Nils Billo, Karen Bissell, Chiang Chen-Yuan, Philippa Ellwood, Asma El Sony, Luis García-Marcos, Javier Mallol, Guy Marks, Neil Pearce, David Strachan
Closing the world data 
gaps for asthma in 
children and adults will 
be a key activity of the 
Global Asthma Network.
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analyses data, oversees publications, and 
develops and maintains the GAN website.
Methods
GAN welcomes participation from centres 
in all countries in the world. In August 2014 
there were 276 centres in 119 countries that 
had expressed an interest in participating in 
GAN (Figure 2). 
Principal Investigators in each centre 
complete surveys about asthma in their 
centre and country. Surveys are of two types: 
on-line surveys of GAN Principal Investigators 
about specific topics, and questionnaire 
surveys undertaken through schools. High 
participation rates are sought in all surveys. 
In 2013/14, GAN surveys of the first type were 
completed, on national asthma strategies, 
asthma management guidelines and access to 
quality-assured, affordable asthma medicines; 
the findings are summarised in Chapters 8, 9 
and 10.
Surveys of the second type are planned to 
start in 2015.  Each centre will be invited to 
undertake a survey using the GAN protocol 
and questionnaires. Two age groups of 
children will be involved (13-14 year olds and 
6-7 year olds), as well as parents/caregivers of 
each child.  The adolescents and the parents 
of the children will be asked to complete 
questionnaires based on ISAAC, including 
additional questions on asthma management 
and the environment; for the adults, questions 
will be based on the European Community 
Respiratory Health Survey. 
Participants will be selected from 
randomly sampled schools within a specified 
geographical area (or all schools) around each 
study centre. Within each country at least one 
urban and one rural centre will be sought 
so that the different influences of these 
environments on asthma can be explored. 
A sample size of 3000 per age group per 
centre will be used to give sufficient power to 
detect differences in the severity of asthma. 
For smaller populations, such as a small 
island nation, all pupils (and their parents/
caregivers) of the age group will be selected. 
Tools to enable centres to follow and use the 
methodology will be available on the GAN 
website.
Impact
GAN is currently the only global study of 
asthma in populations (following on from the 
ISAAC programme) and will contribute new 
information on adult as well as childhood asthma. 
GAN connects with others who strive for a world 
where no-one suffers from asthma and has 
established communication with worldwide 
organisations concerned with respiratory 
health and non-communicable diseases (NCDs), 
especially in low-and middle-income countries.
ISAAC demonstrated that asthma and 
allergies are global health problems and that 
environmental factors are key. GAN is continuing 
this work. The value of GAN is attested to by the 
large number of centres that have expressed an 
interest in participating, and the fact that major 
international respiratory and NCD advocacy 
organisations involved in monitoring and 
preventing chronic respiratory disease have 
expressed their support for GAN. 
GAN has set ambitious targets to decrease 
severe asthma by 50% by 2025 and to increase 
the access to quality-assured essential asthma 
medicines (Figure 1). If these targets are achieved, 
then the burden of, and suffering from, asthma in 
• proportion of symptomatic people with asthma 
 not on inhaled corticosteroids
• time off work/school because of asthma
• unplanned visits for asthma
• hospital admissions for asthma
• severity of asthma
• mortality from asthma
Decrease severe asthma by 50% by 2025
Increase the access to quality-assured 
essential asthma medicines by 2018:
• On the WHO prequalification list - 2014
• On National Essential Medicines Lists - 2015
• Available in all countries - 2018
• Affordable in all countries - 2018
Figure 1: 
Targets of the Global Asthma Network
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Strive for a world where no-one 
suffers from asthma.
Be the asthma surveillance hub 
for the world.
Raise the profile of asthma as a 
non-communicable disease.
Stimulate and encourage 
capacity building in low- and 
middle-income countries.
Promote access to appropriate 
management of asthma.
Research ways of reducing the 
burden of asthma.
ASPIRATIONS OF  THE     
GLOBAL ASTHMA NETWORK
Empowerment
Solidarity
Independence
Quality
Accountability
VALUES OF THE GLOBAL 
ASTHMA NETWORK
Mission of the Global 
Asthma Network:
To prevent asthma and 
improve asthma care 
globally with a focus on 
low- and middle-income 
countries. 
The network will achieve 
this through enhanced 
surveillance, research, 
capacity building, and 
access to effective 
asthma care, including 
quality-assured essential 
medicines.
Vision of the Global 
Asthma Network:
A world where no-one 
suffers from asthma.
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the world will be markedly reduced.
Conclusion
GAN seeks to build on the work of ISAAC and 
The Union to lessen the suffering from asthma in 
the world through surveillance of asthma, research, 
capacity building, improving access to effective 
asthma management and care, including quality-
assured essential medicines, and to advocate for 
asthma to be high on the public health agenda.
Health professionals in all 
countries should ensure that 
their country is represented in 
the Global Asthma Network.
Key Recommendation
Figure 2: 
Global Asthma Network participating centres, August 2014
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Asthma does not have 
to be a burden or 
cause suffering.
PART ONE:   
THE BURDEN OF 
ASTHMA
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Figure 1: Prevalence of asthma symptoms among 13-14 year olds (ISAAC).
The shows  
the centres 
reporting 
the highest 
prevalence
Source: Lai CKW, et al. Thorax 2009
≥20%
10 to <20%
5 to <10%
<5%
Asthma, a disease of the airways, 
occurs in people of all ages, and 
wheeze is the most common 
symptom. The most recent revised 
global estimate of asthma suggests 
that as many as 334 million people 
have asthma, and that the burden 
of disability is high. The historical 
view of asthma being a disease of 
high-income countries no longer 
holds: most people affected are in 
low- and middle-income countries, 
and its prevalence is estimated 
to be increasing fastest in those 
countries. Ongoing monitoring is 
needed to follow the epidemic of 
asthma and its management. 
What is asthma? 
Asthma is a disease of the bronchial tubes 
in the lungs (the “airways”). People with asthma 
typically experience “wheezing”, a high-pitched 
whistling sound heard during breathing, 
especially when breathing out. However, 
wheezing does not always occur, and asthma 
can also involve breathlessness, chest tightness 
or coughing. The underlying process includes 
chronic inflammation of the airways, reversible 
obstruction of the flow of air in and out of the 
Global Burden of 
Disease due to  
Asthma2. Guy Marks, Neil Pearce, David Strachan, Innes Asher
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Figure 2: Prevalence of severe asthma among 13-14 year olds   
          (ISAAC).
≥7.5%
5 to <7.5%
2.5 to <5%
<2.5%
Source: Lai CKW, et al.  Thorax 2009
airways, and the tendency of the airways to 
over-react to stimuli. Asthma most commonly 
develops in early childhood, and more than 
three-quarters of children who develop asthma 
symptoms before age 7 no longer have symptoms 
by age 16. However, asthma can develop at any 
stage in life, including adulthood.
How many people have 
asthma?
The number of people with asthma in the 
world may be as high as 334 million. This figure 
comes from the most recent comprehensive 
analyses of the Global Burden of Disease Study 
(GBD) undertaken in 2008-2010. A lower figure 
of 235 million used in the Global Asthma Report 
2011 came from the most up-to-date GBD 
information available at that time based on 
Asthma is a common chronic 
disease that affects millions 
of people of all ages in all 
parts of the world. It is a cause 
of substantial burden, often 
causing a reduced quality of 
life. New surveys are needed to 
update asthma trends.
 17
analyses from 2000-2002.  These numbers are 
not precise, rather they are estimated from the 
best data available. However, as the following 
paragraphs illustrate, there are many gaps in 
asthma statistics. There is no evidence that the 
number of people with asthma in the world 
has increased from 235 to 334 million between 
our 2011 and 2014 reports; rather this situation 
illustrates the need for high quality data on 
asthma to be collected in an ongoing way. 
Much of the information on which the later 
estimate is based is already out of date, as the last 
global surveys of the proportion of the population 
who have asthma (that is, prevalence) were 
carried out about 10 years ago. Unfortunately 
the World Health Organization (WHO) is not 
undertaking any future global asthma monitoring 
work; however the Global Asthma Network (GAN) 
plans to continue this work with worldwide 
studies to find out how the pattern of asthma is 
changing in children and adults (See Chapter 1).
To make comparisons of the prevalence of 
asthma between different parts of the world, 
and changes over a period of time, standardised 
measurements are needed (that is, measurements 
done in the same way at different places and 
times). The most common way of doing this is 
by questionnaire, which is feasible for large scale 
surveys. Using this approach The International 
Study of Asthma and Allergies in Childhood 
(ISAAC) undertook its latest survey between 2000 
and 2003.
ISAAC found that about 14% of the world’s 
children were likely to have had asthmatic 
symptoms in the last year and, crucially, the 
prevalence of childhood asthma varies widely 
between countries, and between centres within 
countries studied (Figure 1). These conclusions 
resulted from ISAAC’s ground-breaking survey 
of a representative sample of 798,685 children 
aged 13-14 years in 233 centres in 97 countries. 
(A younger age group of children (6-7 years) 
was also studied by ISAAC and the findings 
were generally similar to the older children). 
These adolescents were asked whether they 
Figure 3: Prevalence of symptoms of asthma in the past 12 months among persons aged 18 to 45 
years in 70 countries, World Health Survey 2002-2003. Source: To T,  et al. BMC Public Health 2012. 
0 - 10%
> 10% - 15%
> 15% - 20%
> 20% - 25%
> 25%
No standardised data 
available
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Source: Institute for Health Metrics and Evaluation 
(IHME). 
Figure 4: 
Burden of disease, 
measured by disability 
adjusted life years 
(DALYs see explanation p20) 
per 100,000 population 
attributed to asthma 
by age group and sex. 
Global population, 2010.
had experienced wheeze in the preceding 12 
months. Prevalence of recent wheeze varied 
widely (Figure 1). The highest prevalence (>20%) 
was generally observed in Latin America and in 
English-speaking countries of Australasia, Europe 
and North America as well as South Africa. 
The lowest prevalence (<5%) was observed in 
the Indian subcontinent, Asia-Pacific, Eastern 
Mediterranean, and Northern and Eastern 
Europe.  In Africa, 10-20% prevalence was mostly 
observed.
In this same survey, the prevalence of 
symptoms of severe asthma in the preceding 12 
months, defined as 4 or more attacks of wheeze, 
waking at night with asthma symptoms one 
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or more times per week, and/or any episodes 
of wheeze severe enough to limit the ability to 
speak, also varied substantially, but was > 7.5% in 
many centres (Figure 2).
The prevalence of asthma in younger adults 
varies widely as it does in children. Overall, 4.3% 
of respondents to WHO’s World Health Survey 
aged 18-45 in 2002-2003 reported a doctor’s 
diagnosis of asthma, 4.5% had reported either 
a doctor’s diagnosis or that they were taking 
treatment for asthma, and 8.6% reported that 
they had experienced attacks of wheezing or 
whistling breath (symptoms of asthma) in the 
preceding 12 months (Figure 3). The highest 
prevalence was observed in Australia, Northern 
and Western Europe and Brazil. The World Health 
Survey, which was conducted about the same 
time as ISAAC, used a different survey method 
which may contribute to some of the differences 
in the findings within a region. The prevalence 
of asthma was measured by questionnaire 
administered to 177,496 persons aged 18 to 45 
years living in 70 countries. 
Much less is known about the prevalence of 
asthma in middle-aged and older adults. This 
reflects both a paucity of survey data and the 
greater difficulty of distinguishing asthma from 
other respiratory conditions, such as chronic 
obstructive pulmonary disease (COPD) in 
older age groups. There are no internationally 
standardised comparisons of asthma prevalence 
in the elderly.
Is asthma becoming more or 
less common?
Asthma symptoms became more common 
in children from 1993 to 2003 in many low- and 
middle-income countries which previously had 
low levels, according to ISAAC. However, in most 
high-prevalence countries, the prevalence of 
asthma changed little and even declined in a 
few countries. Factors responsible for increasing 
asthma rates are not fully understood, but 
environmental and lifestyle changes play the key 
roles (see Chapter 7). What has happened to the 
prevalence and severity of asthma since 2003? We 
do not know because there have been no surveys. 
What is the impact of 
asthma on rates of disability 
and premature death?
The burden of asthma, measured by disability 
and premature death, is greatest in children 
approaching adolescence (ages 10-14) and 
the elderly (ages 75-79) (Figure 4). The lowest 
impact is borne by those aged 30-34.  The 
burden is similar in males and females at ages 
below 30-34 years but at older ages the burden 
is higher in males. This sex difference increases 
with increasing age. Figure 4 shows the GBD’s 
measure of health loss attributable to specific 
diseases, for asthma. The GBD used mortality 
statistics and health survey data, where available, 
to estimate, for many countries of the world, two 
components of disease burden: years of life lost 
due to premature death, and years of life lived 
with disability. The latter quantifies both the 
extent of disability and its duration. The years of 
life prematurely lost, and the years of life lived 
with disability are added together and expressed 
as disability adjusted life years (DALYs), which is 
the measure of burden of disease. 
Among people aged less than 45 years, 
most of the burden of disease is disability. The 
GBD estimated that asthma was the 14th most 
important disorder in terms of global years lived 
with disability.  However, for people in older 
age groups, premature death due to asthma 
contributes more to the burden of disease (Figure 
5). 
Asthma has a global distribution with a 
relatively higher burden of disease in Australia 
and New Zealand, some countries in Africa, the 
Middle East and South America, and North-
Western Europe (Figure 6).
Conclusion
The global burden of disease due to asthma 
has become better understood through 
standardised measurement of the proportion of 
the population who have asthma, severe asthma, 
disability due to asthma and/or who have died 
from asthma.  Little is known about asthma in the 
many countries where it has not been studied, 
and little information is available about asthma in 
adults over the age of 45.
Governments should commit 
to research, intervention, and 
monitoring to reduce the burden 
of asthma in the world. Global 
surveillance of asthma requires 
standardised measures of 
asthma implemented in large 
scale surveys of both children 
and adults in diverse settings 
worldwide.
Key Recommendation
• 334 million people have asthma.
• 14% of the world’s children 
experience asthma symptoms.
• 8.6% of young adults (aged 18-45) 
experience asthma symptoms. 
• 4.5% of young adults have been 
diagnosed with asthma and/or 
are taking treatment for asthma.
• The burden of asthma is greatest 
for children aged 10-14 and the 
elderly aged 75-79.
• Asthma is the 14th most 
important disorder in the world in 
terms of the extent and duration 
of disability.
THE GLOBAL BURDEN OF  
ASTHMA: CURRENT ESTIMATES
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Figure 5:
Components of disability 
adjusted life years 
(DALYs): years lived with 
disability (YLD) and 
years of life lost (YLL) 
per 100,000 population 
attributed to asthma 
by age group. Global 
population, 2010. (see DALY 
explanation on p20)
Figure 6: Disability adjusted life years (DALYs) per 100,000 population attributed to asthma by   
          country, both sexes, 2010.
Source: Institute for Health Metrics and Evaluation 
(IHME). 
Source: Institute for Health Metrics and Evaluation (IHME). 
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Hospital Admissions
for Asthma 
Hospital admissions for asthma have 
been proposed as a target indicator 
of improvements in asthma care, but 
the factors underlying variations in 
hospital admission rates are poorly 
understood. Admission to hospital 
during an asthma attack may indicate 
the first episode in the disease 
or a failure of preventive care for 
established asthma. Hospital care 
may be important to prevent a fatal 
outcome in severe or troublesome 
asthma. Historically, the relationship 
between asthma prevalence, severity, 
admissions, and mortality rates in 
high-income countries has been 
complex. Changes in the admission 
rate over time correlate (albeit 
imperfectly) with changes in the 
prevalence and severity of childhood 
asthma. However, the relative ranking 
of national admission rates for asthma 
is not consistent between children and 
adults.
David Strachan, Ramyani Gupta, Luis García-Marcos3.
Hospital admissions for asthma 
may be used as an indirect 
indicator of the burden of 
more severe asthma and the 
efficacy of care. However the 
factors underlying variations 
in hospital admission rates are 
poorly understood and need 
more research.
International Comparisons
Many attacks of asthma are mild and self-
limiting and never present for hospital treatment.  
The proportion of acute episodes which result 
in hospital admission varies greatly between 
countries, depending upon the accessibility and 
affordability of the health care system, the local 
thresholds for referral from community to hospital, 
and from outpatient or emergency visits to 
inpatient care. 
National hospital admission statistics are 
mainly limited to high-income countries in Europe, 
North America and Australasia. Data are lacking 
for most low- and middle-income countries. In 
European countries, among all age groups, asthma 
contributes 0.6% of hospital admissions and 0.4% 
of all inpatient bed-days.  Figure 1 shows an almost 
tenfold variation in age-standardised admission 
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Figure 1: 
Age-standardised 
admission rates for 
asthma for earliest and 
latest available year in 
European countries 
ordered by latest 
admission rate.
Note: earlier data corresponds 
approximately to the International 
Study of Asthma and Allergies in 
Childhood (ISAAC) Phase Three study 
period.  
* No data available for earliest time   
   period.
† No data available for latest time        
   period.
Source: WHO Hospital Morbidity Database, 
accessed November 2013, plus Eurostat (for some 
earlier data).
Age-standardised discharge rate per 100,000
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rates for asthma between European countries in 
recent years.
These all-ages rates conceal considerable 
variation in hospital admission rates between 
children (where rates are generally higher) 
and adults. Caution should be exercised when 
interpreting geographical differences and trends 
over time in asthma admission rates for pre-
school children (where diagnostic overlap with 
acute bronchitis and bronchiolitis may occur) 
and for older adults (where chronic obstructive 
pulmonary disease may be confused with 
asthma). 
Among 23 European countries, in recent 
years, there were close correlations between the 
national admission rates for younger and older 
children, and between younger and older adults 
(see Appendices Figures 1-3), but the correlations 
between rates for adults and children are less 
impressive (Figure 2).
Trends over time
In most, but not all, European countries, age-
standardised asthma admission rates declined 
through the last decade (Figure 1).  In some 
countries, the reduction was two-fold or greater, a 
larger change than has been proposed as a target 
indicator of improvements in asthma care, for 
example by the Global Initiative for Asthma (GINA)
and the Global Asthma Network. This recent 
decline is largely due to a reduction in admission 
rates among children, which is part of a longer-
term rise and fall, peaking in the early 1990s. 
This is shown schematically in Figure 3 (based on 
data from several European countries, the United 
States of America, Canada, Australia, New Zealand, 
Hong Kong and Singapore).
Taking a 50-year perspective, the “epidemic” 
of asthma admissions bears no temporal 
relationship to two epidemics of asthma mortality 
(in the 1960s and the 1980s, related to the use 
of older asthma relievers with potentially toxic 
side effects), nor to time trends for self-reported 
asthma prevalence (Figure 3). However, data from 
the United Kingdom show a peak of primary care 
contacts for acute asthma, particularly among 
children, in the early 1990s, similar to that of 
asthma hospital admissions. This suggests a 
rise and fall in the incidence of asthma attacks 
in the community, rather than simply a change 
in patterns of referral to secondary care, or a 
reduction in the severity threshold for admission 
to the hospital ward.
An international comparison of time trends in 
asthma admissions and asthma drug sales in 11 
countries during the 1990s found that increased 
sales of inhaled corticosteroids (“preventer” 
medication) were associated with a decline in 
rates of hospital admissions for asthma. However, 
inhaled corticosteroids became more widely 
used for asthma during the 1980s, a period 
of increasing hospital admission rates among 
children. Thus, it is not possible to draw firm 
conclusions about the extent to which uptake 
of effective “preventer” medication has reduced 
hospital admission rates for asthma in high-
income countries.
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Figure 2: 
Asthma admission rates for European countries, age 5-14 v 
20-44 years. Relationship of hospital 
admissions to other 
measures of the burden of 
asthma
When national asthma admission rates 
for children were compared with the asthma 
symptoms prevalence and severity data for 
centres (but not whole countries) participating in 
the International Study of Asthma and Allergies 
in Childhood (ISAAC) Phase One study around 
1995, a highly significant positive correlation was 
found between national admission rates and the 
prevalence of more severe asthma symptoms in 
13-14 year olds (14 countries), but not in 6-7 year 
olds (11 countries).  However, a similar analysis 
(prepared for this chapter) of ISAAC Phase Three 
data (collected around 2002) for 15 European 
countries with data in the older age-group, and 
11 European countries in the younger age-group, 
found no statistically significant correlations 
between how the countries ranked against each 
other for national admission rates in children 
and how they ranked for any measure of wheeze 
or asthma prevalence, including more severe 
symptoms.
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Such comparisons need to be interpreted with 
caution, because ISAAC centres are self-selected and 
are not necessarily representative of the countries in 
which they are located. Additionally, between-country 
comparisons at a single point in time are potentially 
biased in many ways. However, some of these biases 
become less relevant if within-country changes are 
examined over time.
For countries with ISAAC study centres participating 
in both Phase One and Phase Three, Figure 4 plots the 
annual change in childhood hospital admission rates 
(~1995-2002) against the change in the prevalence 
of wheeze causing 13-14 year old children to wake at 
night at least once a week. Over this period, admission 
rates declined in all these countries except Hong Kong 
and Poland. There was a significant positive correlation 
between the decline in prevalence of severe asthma 
symptoms between Phase One and Phase Three and 
the decline in the corresponding national admission 
rates for childhood asthma over a similar period.  
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Figure 4: 
Annual change in 
hospital admission 
rates for childhood 
asthma (ages 5-14) by 
change in prevalence 
of nocturnal wheezing 
among 13-14-year-olds 
in countries with one 
or more ISAAC centres 
providing prevalence 
data for both ISAAC 
Phase One (around 1995) 
and ISAAC Phase Three 
(around 2002). 
Sources: National admissions data from Anderson 
HR et al. IJE 2008;  (updated by WHO Hospital 
Morbidity Database). Prevalence data fom Pearce 
NE et al. Thorax 2007.
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Conclusion
Asthma admission rates have been proposed as 
a target indicator for monitoring progress towards 
improved asthma care. Large reductions in admissions 
have occurred already over the last decade in several 
countries.
However, currently routinely collected information 
is almost entirely restricted to high-income countries, 
limiting the value of admission rates for surveillance 
of the global burden of asthma. Large unexplained 
changes in admission rates have occurred over the 
past 25 years, particularly for childhood asthma, but 
international correlations of within-country change in 
prevalence versus within-country change in admission 
rates provide some support for the concept that 
changes in hospital admission rates can be used as an 
indirect indicator of the burden of more severe asthma 
in the community. 
In countries which routinely collect admissions 
data, changes in hospital admissions over time may 
be used as an indirect indicator of the burden of more 
severe asthma. Before admission rates can be used as 
an indirect indicator of the global burden of severe 
asthma, more  countries need to collect admissions 
data.
Health authorities in all 
countries should collect counts 
of hospital admissions in 
children and adults from defined 
catchment populations, to 
monitor trends in asthma over 
time. 
Key Recommendation
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Deaths due to asthma are 
uncommon but are of serious 
concern because many of them are 
preventable. Most deaths certified 
as caused by asthma occur in older 
adults, although comparisons of 
mortality rates have tended to focus 
upon children and younger adults. 
Over the past 50 years, mortality 
rates in these younger age groups 
have fluctuated markedly in several 
high-income countries, attributed to 
changes in medical care for asthma, 
especially the introduction of new 
asthma medications.
David Strachan, Elizabeth Limb, Neil Pearce, Guy Marks4.
International comparisons
Asthma is a rare cause of mortality, 
contributing to less than 1% of all deaths in most 
countries worldwide. Rates of death from asthma 
rise almost exponentially from mid-childhood to 
old age, so the majority of asthma deaths occur 
after middle age. However, there is considerable 
potential for diagnostic confusion with other 
forms of chronic respiratory disease in the older 
age groups, so comparisons of mortality rates 
have tended to focus on children and younger 
adults.
International mortality statistics for asthma 
are limited to those countries reporting a full 
set of causes of death. Figure 1 compares the 
mortality rates (age-standardised) for asthma 
among countries reporting asthma separately 
in recent years (around 2010). For some of the 
less populous countries with few asthma deaths, 
there is a substantial range of uncertainty around 
the published rate. However, among the more 
populous countries there is a 100-fold variation 
in age-adjusted rates, for instance between the 
Netherlands (low) and South Africa (high). 
When the comparisons are limited to 5-34 
year olds (Figure 2), numbers of deaths are fewer 
and margins of error are larger, but the disparities 
persist.
Trends over time
The Global Burden of Disease (GBD) Study 
estimates that age-standardised death rates from 
Asthma Mortality
Avoidable asthma 
deaths are still 
occurring due to 
inappropriate 
management of 
asthma, including 
over-reliance on 
reliever medication 
rather than preventer 
medication.
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Figure 1: 
Age-standardised 
asthma mortality rates 
for all ages 2001-2010 
from countries where 
asthma is separately 
coded as a cause of 
death, ordered by 
mortality rate and 
country income group.*
Source: WHO Detailed Mortality Database, 
February 2014 update.
*Data standardised to the World Standard 
Population. Calculated from the average number 
of deaths and average population for each 5-year 
age-group over the period 2001-2010, using all 
available data for each country (the number of 
available years over this period ranged from 1 
to 10). 
Age-standardised deaths per million population
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Figure 2: 
Age-standardised 
asthma mortality rates 
for ages 5-34 years 
only, 2001-2010 from 
countries where asthma 
is separately coded as a 
cause of death, ordered 
by mortality rate and 
country income group.*
Source: WHO Detailed Mortality Database, 
February 2014 update.
*Data standardised to the World Standard 
Population. Calculated from the average number 
of deaths and average population for each 5-year 
age-group over the period 2001-2010, using all 
available data for each country (the number of 
available years over this period ranged from 1 
to 10). 
Age-standardised deaths per million population
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asthma fell by about one-third between 1990 
and 2010: from 250 per million to 170 per million 
among males, and from 130 per million to 90 per 
million among females. These worldwide figures 
include all ages.
More detailed comparisons have been 
made over a longer time period in high-income 
countries, focussing on younger age groups. 
Over the past half-century, there have been two 
distinct peaks in asthma mortality in a number of 
high-income countries (Chapter 3, Figure 3). 
The first, during the mid-to-late 1960s, 
represented an approximately 50% increase in 
asthma death rates among 5-34 year olds. It is 
generally attributed to the introduction of high-
dose isoprenaline inhalers as an asthma reliever 
medication, which can have toxic effects on the 
heart during acute asthma attacks. When these 
medications were withdrawn, the 1960s epidemic 
of asthma deaths subsided.
The second epidemic, during the mid-1980s, 
represented an increase of approximately 38% 
in asthma death rates among 5-34 year olds. In 
at least some of the affected countries, it was 
probably due to the widespread use of fenoterol, 
another inhaled asthma medication with 
potential cardiac toxicity. However, this second 
epidemic was also observed in some countries, 
such as the United States of America, where 
fenoterol was never approved or widely used.
Relationship of mortality 
to other measures of the 
burden of asthma
Taking a 50-year perspective, the epidemics 
of asthma mortality (related to the use of older 
asthma relievers with potentially toxic side 
effects) understandably bear little relationship 
to the time trends for asthma prevalence or 
hospital admission rates for asthma. In several 
high-income countries, asthma admission rates 
among children rose to a peak in the 1990s, 
after the 1980s peak in asthma mortality. 
However, both hospital admission rates and 
asthma mortality rates among children have 
been declining since 2000 in countries where 
they have been measured, whereas asthma 
prevalence has been stable or rising in many 
countries (Chapter 3, Figure 3).
When national asthma mortality rates for 
children were compared with the asthma 
symptoms prevalence and severity data for the 
International Study of Asthma and Allergies 
in Childhood (ISAAC) Phase One centres in 
the same countries, a significantly positive 
correlation was found between childhood 
asthma mortality and the prevalence of more 
severe asthma symptoms in both 6-7 year 
olds (29 countries) and 13-14 year olds (38 
countries). 
Such comparisons need to be interpreted 
with caution, because ISAAC centres are not 
necessarily representative of the countries 
in which they are located. However, when 
comparing mortality and hospital admission 
rates, national data can be used in both 
instances. Figure 3 shows this comparison for 
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Age-standardised asthma mortality rates v admission rates, European 
countries 
Rank correlation:
r = 0.44, p = 0.03
24 European countries which have reported 
recent data for both outcomes. There is a 
significantly positive correlation between 
mortality and admission rates for asthma at all 
ages. 
Avoidable factors in asthma 
deaths
Although asthma mortality rates have 
declined in many high-income countries, 
confidential enquiries in the United Kingdom 
have suggested that avoidable factors still play 
a part in the majority of asthma deaths. 
The most recent comprehensive review, 
of 195 asthma deaths in the United Kingdom 
during 2012-2013, found that nearly half died 
without seeking medical assistance or before 
emergency medical care could be provided, and 
the majority were not under specialist medical 
supervision during the year prior to death. 
Only one-quarter had been provided with a 
personal asthma action plan, acknowledged to 
improve asthma care, and there was evidence 
of excessive prescribing of short-acting reliever 
medication, under-prescribing of preventer 
medication, and inappropriate prescribing 
of long-acting beta-agonist bronchodilator 
inhalers as the sole form of treatment. 
These observations, from a high-income 
country with a tradition of evidence-based 
medicine and a national health service which is 
free at the point of use, suggest that improved 
access to appropriate asthma medication 
is a key goal in reducing asthma mortality 
worldwide.
Conclusion
Asthma deaths represent the “tip of the 
iceberg” with respect to the global burden of 
asthma. Although the risk of any individual 
asthmatic patient dying of their disease is 
thankfully very low, continued surveillance of 
asthma mortality rates is essential to monitor 
progress in asthma care, and as an early 
warning of epidemics of fatal asthma, as have 
occurred in the past half-century.
Figure 3: 
Age-standardised 
asthma mortality rates 
and age-standardised 
hospital admission rates 
for asthma, in European 
countries providing 
recent data for both 
(2001-2010). 
Sources: WHO Detailed Mortality Database, 
February 2014 update, WHO Hospital Morbidity 
Database, accessed November 2013.
Age-standardised asthma admission rate per 100,000
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Health authorities in all 
countries should report rates 
of asthma deaths in children 
and adults to monitor progress 
in asthma care and as an early 
warning of epidemics of fatal 
asthma. 
Key Recommendation
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Javier Mallol, Luis García-Marcos, Paul Brand5.
International Study on 
Wheezing in Infants 
The largest multi-centre study of wheezing 
in the first year of life, the International Study on 
Wheezing in Infants (Estudio Internacional de 
Sibilancias en Lactantes, EISL), has contributed 
new information about therapeutic approaches 
to recurrent wheezing (RW).  Data from this cross-
sectional study including 30,093 children in 17 
centres: 25,030 in 12 centres in Latin America and 
5,063 from 5 centres in Europe were published 
in 2010 (Figure 1). RW in the first year of life, 
defined as having three or more episodes of 
wheezing during that time, is common (20%), with 
a high proportion of these infants suffering from 
frequent and severe episodes.  EISL found that 
32.2% of infants with RW have 7 or more episodes 
(32.3% in Latin America and 31.8% in Europe); 
71% reported visits to the Emergency Department 
(ED) due to wheezing (74% in Latin America and 
55% in Europe); and 26.8% reported admission 
for wheezing during the first year of life (28.4% 
in Latin America and 14.2% in Europe) (Figure 
2). Overall, these figures imply a high burden of 
health costs for countries and parents in terms of 
use of health facilities and medications.  
The Common Cold
EISL found a strong association between 
RW during the first year of life (both in affluent 
and non-affluent countries) and: common viral 
respiratory illnesses (the symptoms of such 
illnesses are that of a cold) during the first 3 
months of life; attending day-care; wheezing in 
the first three months of life; male gender; the 
mother smoking during pregnancy; and family 
history of asthma or rhinitis. Breast feeding for 
>3 months and high maternal education showed 
a protective effect.  Thus, avoiding smoking 
during pregnancy, delaying day-care attendance, 
breastfeeding babies for at least 3 months, and 
improving maternal education could be effective 
strategies for decreasing the prevalence of RW. 
Wheezing in Infants
Recurrent wheezing in infants is the 
most common clinical expression 
of asthma at that age.  It should 
no longer be considered a benign 
condition that disappears later in 
childhood, particularly because 
many of these infants develop 
frequent and severe episodes. 
Early diagnosis and effective 
management of troublesome 
recurrent wheezing may decrease 
the high proportion of infants with 
recurrent wheezing who have 
severe episodes as well as visits to 
the Emergency Department and 
admissions for wheezing during the 
first year of life.
Recurrent wheezing in 
infants, particularly if 
they are presenting with 
frequent and/or severe 
episodes, should be 
diagnosed and managed 
as asthma, unless 
there is evidence to the 
contrary.
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There is increasing evidence that having a 
cold in the first year of life plays an important 
role in the commencement and/or maintenance 
of wheezing and asthma in early life. Wheezing 
illnesses in infants, caused by human rhinovirus 
and respiratory syncytial virus (RSV) among 
other things, are robust predictors of subsequent 
development of asthma, decreased lung function, 
and increased bronchial responsiveness in school 
age children. Common cold viruses are by far the 
most frequent cause of asthma exacerbations at 
any age.
While there is no consensus on the 
effectiveness of medical interventions for RW in 
the first year of life, these infants - particularly 
if episodes are frequent and/or severe - are 
frequently treated with asthma medicines, both in 
hospitals and in primary care. Ninety-one percent 
of infants with RW used inhaled bronchodilators 
and 46% used inhaled corticosteroids (ICS) with 
differences between regions (Figure 2). Evidence-
based guidelines also suggest using clinical 
severity signs (higher frequency and severity of 
wheezing episodes) as key indicators for starting 
therapy with ICS in preschool wheeze, with the 
aim of decreasing the number and severity of 
wheezing exacerbations. The ways that wheezing 
is classified in preschool children in clinical and 
epidemiological studies do not reliably predict 
the outcome of wheeze over time or the response 
to ICS treatment. In addition, these classifications 
of wheezing are difficult to identify in clinical 
practice and can even change within the first year 
of life. Thus these classifications of wheeze are 
not helpful for clinicians when they are deciding 
treatment for infants with RW.
Management
The effectiveness of ICS in treating children 
with more severe or persistent symptoms of 
preschool wheeze in children over 12 months of 
age is well established. In EISL the high proportion 
of infants with severe symptoms of RW leading to 
ED visits, hospital admissions, sleep disturbance, 
and impaired quality of life, may be partly 
explained by poor recognition and management 
of infants with troublesome recurrent asthma 
symptoms.  Contributing factors may include 
a reluctance to diagnose asthma in young 
children, a delay in starting proper treatment, 
prescription of medicines with doubtful efficacy 
(antileukotrienes) or proven absence of efficacy 
(antibiotics, cough syrups, antihistamines, among 
others), or poor education of parents about how to 
use inhalers and spacers. We suggest outcomes for 
infants with RW would be improved if the use of 
ICS could be improved, i.e. a sufficient dose taken 
over a sufficient time with good adherence.      
Figure 1:  Prevalence of recurrent wheezing during the first year of life in European and Latin   
 American centres.   
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Figure 2: 
Reported severity, medications and other variables in infants with recurrent wheezing during the 
first year of life. Source: Mallol J, et al. Thorax. 2010.
Response (%)
Health professionals in all 
countries should regard frequent 
or severe recurrent wheezing in 
infancy as part of the spectrum 
of asthma.
Key Recommendation
Conclusion
The EISL data strongly supports the need 
for efficient, realistic, and easy-to-implement 
strategies for the education and management 
of infants with recurrent asthma symptoms, 
directed at both parents and health care 
workers, especially in developing countries. Early 
identification and proper management of infants 
with recurrent troublesome asthma symptoms 
is likely to decrease the prevalence of severe 
episodes, ED visits and hospital admissions, 
use of inappropriate medications, and other 
complications. This requires a paradigm shift: 
health care workers and authorities should no 
longer consider RW in infancy, especially when 
frequent and/or severe episodes are present, as a 
benign condition. 
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The Economic 
Burden of Asthma  
It is difficult to quantify the global 
economic burden of asthma, but 
estimates for separate countries 
and regions are tremendously 
high. The indirect costs of 
asthma, especially its negative 
impact on productivity, is at 
least as large as its direct costs. 
Attempts to reduce the economic 
burden of asthma should move 
towards better management 
of asthma. Improving access 
to care and adherence to 
evidence-based treatment can 
reduce the economic burden 
of asthma, even in locations 
where prevalence is rising.  
 
Challenges in estimating the 
global economic burden of 
asthma 
Diseases can cause economic loss in a number 
of ways. They can impose direct costs through 
consumption of resources (e.g., hospitalisations, 
physician visits, and medications), as well as 
indirect costs through loss of productivity. 
Globally, as a major non-communicable disease, 
asthma creates a tremendous economic burden, 
although the exact quantification of this burden 
is challenging. What is clear is that the economic 
burden of asthma is high, adding to the need for it 
to be recognised as a public health priority. 
Attaching numbers to the economic burden 
of asthma is fraught with several challenges. 
One challenge is how to attribute resources to 
asthma. For example, it is difficult to tease out 
the contribution of asthma to depression in a 
patient with both conditions, or to attribute how 
many days of sick leave are due to asthma. Even 
estimating the prevalence of asthma, a key factor 
in estimating the burden at the regional and 
national level, is difficult, as seen in Chapter 2, 
given the inconsistencies in definition, as well as 
under-diagnosis and over-diagnosis of asthma in 
different subgroups of individuals.  
What we know about the 
global burden of asthma
Most studies on the burden of asthma are 
from developed countries, where national surveys 
of diseases and large, administrative databases, 
can be interrogated to provide a broad picture 
of the burden. The one systematic review (2009) 
illustrates the variation within countries and the 
relative lack of information from low-and middle-
income countries. A recent study in the United 
States of America estimated that the total cost 
of asthma to society was $56 billion in 2007, or 
$3,259 per person per year (in 2009 US dollars). 
6. Mohsen Sadatsafavi, J Mark FitzGerald
Controlled asthma 
imposes far less of 
an economic burden 
than non-controlled 
asthma. Strategies 
towards improving 
access and adherence 
to evidence-based 
therapies can therefore 
be effective in reducing 
the economic burden 
of asthma in both 
developed and 
developing countries.
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A further European study in 2011 has estimated 
the total cost of asthma in that year to be €19.3 
billion among Europeans aged from 15 to 64 
years (in 2011 Euros). In a separate study in the 
Asia-Pacific region, the sum of direct and indirect 
costs of asthma per person per year ranged from 
$184 in Vietnam to $1,189 in Hong Kong (in 2000 
US dollars). Furthermore, there is a significant 
variation in cost estimates even among the 
studies from the same country. For example, 
US-based estimates of the cost of asthma 
per person vary up to five-fold. Despite the 
heterogeneous settings and different numbers, 
many studies have pointed towards the fact that 
the indirect cost of asthma is at least as large as 
its direct costs. This is not a surprising finding: 
disability from asthma affects individuals who 
are often at the most productive phase of their 
working lives, and parents of dependent children 
with asthma are also often in the workforce. 
Research also suggests that the contribution of 
“presenteeism” (individual loss of function when 
at work) is larger than absenteeism (inability to 
come to work) in patients with asthma. A recent 
Canadian study has shown that, compared with 
controlled asthma, uncontrolled asthma results 
in a $184 (in 2012 Canadian dollars) loss of 
productivity during a week for such a person, 90% 
of which is attributable to presenteeism. 
The preventable burden of 
asthma: the importance of 
clinical control
Currently, asthma cannot be cured, and 
there are limited evidence-based options to 
prevent its development. The emphasis of 
asthma management is therefore focused on 
achieving clinical control with an added priority 
of preventing the future risk of exacerbations. 
Strategies which result in well-controlled asthma 
are associated with a significant reduction in 
economic burden compared to uncontrolled 
disease, as shown by programmes implemented 
in Salvador (Brazil) and Finland (for more 
examples see Chapter 8). Despite the wide 
availability of effective medications for several 
decades, asthma remains uncontrolled in a 
substantial proportion of the population. Thus, 
the incremental economic burden of uncontrolled 
asthma is of particular relevance to decision 
makers as it represents the aspect of the burden 
that is preventable.   
Low adherence as a major 
cause of preventable burden
Research in diverse jurisdictions, including 
both developed and developing countries, has 
consistently shown that adherence to controller 
medications is poor. The evidence linking 
adherence to controller medications with better 
asthma outcomes is strong, making adherence 
a modifiable factor and a potential target for 
reducing the economic burden of asthma.
Improving access to care 
and adherence to evidence-
based medication
Given the proven benefit of existing essential 
asthma medicines for most asthma patients, 
improving access and adherence to such 
treatments should be a major global priority (see 
chapter 12). In developing countries, additional 
barriers to delivering effective management 
may include poverty, poor education, and 
poor infrastructure, indicating that a more 
comprehensive approach is required, including 
political commitment to better asthma care 
(see Chapter 12). In both developing and 
developed countries, improving adherence to 
controller treatment requires education of both 
care providers and patients about its long-term 
benefits. Developing interventions such as shared 
care models for asthma management, or the 
use of communication technologies to facilitate 
interaction between patients and care providers, 
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Governments should measure 
and monitor the economic costs 
of asthma in their countries, 
including health care costs and 
productivity losses.
Key Recommendation
can be beneficial. The role of health literacy and 
the socio-cultural context in which the patients 
find themselves are also important. 
A small fraction (less than 10%) of patients 
with asthma which is difficult to control 
(refractory asthma) do not respond to 
conventional controller therapies and depend 
on treatments that are currently very expensive 
and only accessible in certain parts of the 
world. Reducing the cost of these treatments 
and making them accessible across the world 
will help reduce the burden due to refractory 
asthma. This requires the coordinated efforts 
of industry, government, non-governmental 
organisations (NGOs), and international 
organisations such as the World Health 
Organization (WHO). 
Conclusion
Most countries have not yet estimated the 
costs of asthma. Where it has been estimated, 
the economic burden of asthma is great because 
of direct healthcare costs, and indirect costs, as a 
result of loss of productivity due to people being 
absent from work, or working less effectively 
while at work. The impact of these indirect costs 
would be diminished by improving asthma 
control, through improving access to good 
management including medicines.
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Genetics:  
One part of the picture
Asthma often runs in families, and identical twins are more likely to both be asthmatic 
than are non-identical twins. Nevertheless, only about half of the identical twins with an 
asthmatic co-twin are themselves asthmatic, indicating a contribution from both genetic 
and non-genetic factors.
Large studies of asthma in the general population have recently identified a small 
number of genetic variants that influence asthma risk, mainly in children. These variants 
are frequently found in populations of European origin, but their association with asthma 
is too weak to predict reliably which individuals will develop the disease.
The role of allergy? 
Asthma used to be thought of as an allergic disease, where allergen exposure causes 
sensitisation to allergens and continued exposure leads to the processes in the airway 
which lead to asthma symptoms. While allergy is a potential underlying factor for up 
to half of the people with asthma, the remainder have no allergic features. In low- and 
middle-income countries the proportion of people with non-allergic asthma is greater 
than in high-income countries. Furthermore, some occupational causes of asthma do 
not appear to involve allergy.  These non-allergic mechanisms are currently not well 
understood.
Parental smoking 
(for children) and 
occupational exposures 
(for adults) are the 
clearest examples of 
remediable causes of 
asthma.
Factors Affecting 
Asthma
A wide variety of factors are 
known to affect asthma, but 
no one specific cause, either 
biological or environmental, has 
been identified. Studies indicate 
the contribution of both genetic 
and non-genetic factors. When 
considering non-genetic factors 
affecting asthma, it is important to 
distinguish between the triggers of 
asthma attacks (which are widely 
recognised) and the causes of the 
underlying asthmatic process or 
trait (about which much less is 
known). Both groups of factors 
may contribute to the severity and 
persistence of asthma.
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Common triggers: The 
common cold and exercise
Asthma attacks are commonly triggered by 
upper respiratory tract infections, including 
common colds, and by exercise. Less frequently, 
they are related to tobacco smoke exposure, acute 
emotional stress, or to the consumption of certain 
foods, beverages, or medicines. 
Environmental factors that may provoke 
asthma attacks include inhaled allergens 
(commonly dust mites and animal fur; less 
commonly pollens, moulds, and allergens 
encountered in the workplace); and inhaled 
irritants (cigarette smoke, fumes from cooking, 
heating or vehicle exhausts, cosmetics, and 
aerosol sprays), and medicines (including aspirin). 
Causes of the underlying 
asthma trait - environmental  
factors: Facts and theories 
Environmental factors are much more likely 
than genetic factors to have caused the large 
increase in the numbers of people in the world 
with asthma, but we still do not know all the 
factors which may be important and how they 
interact with each other.
Secondhand smoke is a confirmed risk
Secondhand tobacco smoke has been 
confirmed as a risk for asthma both in childhood 
and adulthood (see references at the end of 
the report).  Pre-natal exposure may also be 
important. This is considered to be a causal 
association, implying that the prevalence (and 
severity) of asthma would be reduced if exposure 
to secondhand smoke could be reduced.  The role 
of other indoor air pollutants, such as cooking on 
an indoor open fire, as causes of the asthmatic 
tendency is less clear and less consistent than for 
tobacco smoke. 
Link to mould and damp is uncertain
Dampness and mould growth are more 
common in the homes of asthmatic children and 
adults. However, the causal nature of this link 
remains uncertain, inviting further research. Few 
people with asthma are demonstrably allergic to 
fungal moulds. Dampness in homes is associated 
with both allergic and non-allergic forms of 
asthma. 
Animals in the home and on the farm
Exposure to furry pets is often less common 
among asthmatic children and adults, due to 
avoidance or removal of pets by allergic families. 
When this is taken into account, there is no 
consistent evidence that pets are either a risk 
factor or a protective factor. 
In contrast, several large studies, mainly 
in temperate countries, have shown a lower 
prevalence of asthma among children living on 
farms. These children also have fewer allergies, 
but this does not totally explain the apparent 
protection against asthma. No specific cause has 
been identified for this protective effect of farm 
upbringing, but diversity of microbial exposure 
may be an underlying factor.
Antibiotics and paracetamol:  
cause or effect?
Asthma symptoms are more common among 
children who were treated with antibiotics in early 
childhood. However, the direction of cause and 
effect here is uncertain. Symptoms of wheezing 
commonly develop for the first time in infancy 
and may be treated with antibiotics before they 
are recognised as the early manifestations of 
asthma. 
Similar considerations of “reverse causality” 
apply to the possible link between paracetamol 
(acetaminophen) exposure in infancy and asthma 
at school age – paracetamol may have been given 
for early symptoms of asthma, or for infections 
that may themselves increase the risk of asthma. 
Recent paracetamol use by adolescents and 
adults is also more common among those with 
asthma symptoms, but this may also be “reverse 
causality”; people with asthma symptoms may 
avoid using aspirin, since it is a known trigger 
of wheezing attacks in a small proportion of 
asthmatics, who use paracetamol instead.
Occupational exposures 
Occupational asthma may develop in persons 
with no previous history of chest disease and can 
sometimes persist after exposure to the causal 
agent is removed. High-risk occupations include 
baking, woodworking, farming, exposure to 
laboratory animals, and use of certain chemicals, 
notably paints containing isocyanates. Perhaps 
the most widespread “occupational” exposure is to 
chemical cleaning agents, both in workplace and 
domestic settings.
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Preventive and remedial 
measures
Eat a balanced diet
Prolonged exclusive breastfeeding was once 
thought to protect against allergic diseases, 
including asthma, but extensive research has 
shown that this is not the case. Many components 
of diet during later childhood and adult life have 
been studied in relation to asthma. The balance 
of evidence suggests that diets that are widely 
recommended to prevent cardiovascular diseases 
and cancer may slightly reduce the risk of asthma. 
A link has been established between obesity and 
asthma, although the mechanisms are not clear.
Avoid exposure to causal agents
Occupational exposures provide some of 
the clearest examples of remediable causes 
of asthma. Special care is required in high-risk 
occupations (baking, woodworking, farming, 
exposure to laboratory animals, and use of 
certain chemicals, notably paints containing 
isocyanates) to minimise inhalation of potentially 
harmful substances, and care to reduce exposure 
to chemical cleaning agents in the home is also 
needed.
Don’t smoke or go near second hand 
smoke
Smokefree environments are important for 
people of all ages. Little is known about the 
factors affecting asthma after middle age, when 
there is substantial overlap between the reversible 
airflow obstruction, which is typical of asthma, 
and the irreversible airflow obstruction of chronic 
obstructive pulmonary disease (COPD). Active 
smoking is a major and remediable cause of 
COPD, and probably contributes to some cases 
of adult-onset asthma. Smoking should therefore 
be discouraged among both asthmatics and non-
asthmatics alike.
Conclusion
Environmental factors are much more likely 
than genetic factors to have caused the large 
increase in the numbers of people in the world 
with asthma. Tobacco smoking and secondhand 
tobacco smoke are avoidable by the individual. 
Occupational exposure is a risk diminishable 
by both workplace practices and government 
policies. These and other factors require further 
research.
Governments should strengthen 
policies to reduce tobacco 
consumption, encourage healthy 
eating, and reduce exposure to 
potentially harmful chemicals, 
smoke, and dust. Funders need 
to support further research to 
identify causes of asthma.
Key Recommendation
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Quality-assured 
asthma medicines 
need to reach 
everyone with 
asthma.
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PART TWO:   
MANAGEMENT 
OF ASTHMA 
AND CAPACITY 
BUILDING
Successfully managed 
asthma 
When asthma is successfully managed, the 
person with asthma will have no symptoms 
or only very mild symptoms, no attacks, no 
emergency department visits, no limitation 
of exercise or activities, no loss of sleep due 
to asthma, minimal use of an asthma reliever 
medicine(<2 times/week), and the least side 
effects possible of asthma medicines. The person 
will have no impediments to their lifestyle due 
to asthma, and will be able to attend their place 
of education or work with no time off due to 
asthma. National asthma strategies are aimed at 
achieving successful management for all people 
with asthma.
Examples of successful 
strategies 
In Finland, patients and society have 
benefitted from the systematic and consistent 
development and implementation of asthma 
management. A comprehensive nationwide 
Asthma Programme was undertaken from 1994 
to 2004 to lessen the burden of asthma on 
individuals and society.  In 2010, it was estimated 
that the total asthma costs (healthcare, drugs, 
disability, and productivity loss) would have been 
€500-800 million annually by then, if nothing had 
been done and if 1990s trends had continued.  
However, the realised costs in 2010 were less than 
half of that, around €200 million. This implied a 
potential cost saving from €300-600 million every 
year, depending on the scenario used. 
National Asthma 
Strategies8.
There are many examples 
worldwide of systematic 
strategies which have successfully 
reduced the burden of asthma, 
in low-, middle- and high-income 
contexts. Properly implemented 
strategies have been proven 
repeatedly to work. From the 
public health perspective, the 
key issue in reducing the burden 
of asthma is to implement 
the best standards of care in 
everyday practice. The benefits 
can be remarkable; systematic 
implementation of the best 
standards of care can reduce 
both human suffering and the 
associated societal costs. It is the 
responsibility of asthma experts 
and healthcare professionals 
to collaborate with national 
public health authorities and 
international organisations 
to improve efficiency in 
management and care. In 2013, 
roughly 1 in 4 countries had 
national asthma strategies in 
place, for children and/or adults.
Tari Haahtela, Olof Selroos Philippa Ellwood, Nadia Aït-Khaled
Outline for a Local Action Plan
Tasks Tools Outcomes
Main Messages
e.g. More life - less asthma
...........................................
...........................................
...........................................
...........................................
For general public,
decision makers
...........................................
...........................................
...........................................
...........................................
e.g. Stop asthma exacerbations
indicator: emergency visits reduced by 50%
(e.g. 3-5 goals for next 5-10 years)
1.
2.
3.
4.
5.
Goals
Quantitative (numerical) goals for health
care professionals
For each Goal: what to do (Tasks), how to do
it (Tools), and what to measure (Outcomes)?
Figure 1: Generic template for a local action plan.
Source: Haahtela T. in: Global Atlas of Asthma. EAACI 2013.
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Several other encouraging examples now 
exist, e.g. in Poland, Portugal, Brazil, and recently 
in Costa Rica. As not all such programmes are 
reported, we encourage publication of strategies 
and outcomes. The problems to be addressed 
are different in high-income compared to low- 
and middle-income countries, and the solutions 
need to be tailored according to local needs and 
resources. There is, however, no question that the 
burden of asthma can be markedly reduced using 
strategies that have been adapted to the local 
societal, economic and health care environments. 
Patients from a low resource setting in Salvador, 
Brazil, received free medication for asthma 
and rhinitis in accordance with international 
guidelines. The outcome was impressive. The 
costs for asthma care were reduced on average 
by US$ 733 per patient per year for the families 
and by US$ 387 per patient per year for the public 
health system. In the entire Salvador population 
a 74% reduction in asthma hospitalisation 
rates occurred after the implementation of the 
programme. The educational effort targeting both 
patients and professionals was paid back in a few 
years. In Benin, in 2008 a pilot study of asthma 
management was conducted. The cohort analysis 
after one year of standardised management (see 
Chapter 12) demonstrated a dramatic decrease in 
asthma severity, the number of exacerbations and 
hospitalisations (see Chapter 14).
Asthma burden can 
be rapidly reduced by 
the implementation of 
relatively simple measures 
within a systematic 
strategy to improve 
early detection and 
provide effective anti-
inflammatory treatment.
Generic Asthma Plan - to be adjusted for local and national needs
Reduce burden, promote health, support people with asthma!
4-Step Action PlanBackground
NEW BODY OF
KNOWLEDGE
EPIDEMIOLOGY
ECONOMY
EVIDENCE
CONCLUSIONS STRATEGIC CHOICES GOALS,
MEASURES
ACTIVITIES
Disability caused by
asthma can be
prevented
Morbidity
Prevalence
Costs
.
. Implementation of
best practice is
highly cost-eective
both on the patient
and societal levels
  
  
 
• Public health 
problem
• Need for broad 
consensus
• Need for action
• Identication of 
key stakeholders
• Focus on patients
• Focus on severe  
asthma to stop 
exacerb/attacks
• Focus on eective 
use of available 
resources and 
registers
• Practical action plan, not a  
consensus report
• Strategies for: 1)those 
diseased, 2)general 
population
• Quantitative and qualitative 
goals
• Focus on primary health 
care and outpatients 
services
• Promotion of asthma health
• Asthma Control Tools for 
guided self-management to 
stop exacerb/attacks
• Search for critical mass for 
change through education 
and counselling
• 1-3 key 
messages for 
the public
• 3-5 numerical  
goals for  
Health Care to 
reduce the  
burden
• Tools to be 
used locally
• Measures to 
follow 
outcomes
• Time lines
• Leadership, steering 
group (local, national)
• Capacity building, 
funding
• New internet-based 
networking with 
specialists, GPs, nurses, 
pharmacists
• In diagnostic work, 
improving early  
detection
• In treatment, improving 
eective use of ICS
• Education and publicity 
(with NGOs)
• Legislation (essential 
medication, anti- 
smoking)
• Feedback, follow-upProcess evaluation
Outcome evaluation
.
.
.
Figure 2: 
Strategic flow 
for an asthma 
plan.
Source: Haahtela T, et al. 
Allergy 2008.
 45
Inhaled corticosteroids are 
essential to success
Asthma projects and programmes in 
Argentina, Australia, Brazil, China, Japan, Mexico, 
the Philippines, Russia, South Africa, and Turkey 
were discussed in 2009 in Berlin by a group of 
experts in asthma care, the Advancing Asthma 
Care Network. Their report “Asthma programmes 
in diverse regions of the world: challenges, 
successes and lessons learnt” concluded that 
the major barriers for all programmes are: 1) low 
rates of dissemination and implementation of 
treatment guidelines, 2) low levels of continuing 
medical education and training of primary 
health care professionals, and 3) poor access 
to and distribution of inhaled corticosteroids. 
Additionally, under-diagnosis and inadequate 
treatment further limit the success of less 
developed programmes. 
All successful asthma programmes seem to 
have the following characteristics: 1) improving 
early diagnosis and the introduction of first-line 
treatment with anti-inflammatory medication 
(mainly inhaled corticosteroids), 2) improving 
long-term disease control, 3) introducing 
simple means for guided self-management to 
proactively prevent exacerbations/attacks, and 
4) effective education and networking with 
general practitioners, nurses and pharmacists. A 
systematic approach is required and must aim 
to motivate and organise. Improvements can be 
achieved with relatively simple means. All the 
main stakeholders should be represented when 
multidisciplinary actions are being planned. 
Especially important is the involvement of 
the non-governmental patient organisations, 
which are aware of the grass-root problems. Any 
programmes should set 3-5 goals, preferably 
accompanying each with at least one quantifiable 
indicator and target. For example, one goal could 
be to reduce asthma exacerbations, measured by 
the number of emergency visits, with the target 
of reducing emergency visits by 50% over the 
next 3-5 years. For each goal, more specific targets 
(what to do?), tools (how to do it?) and outcomes 
(what to follow and measure?) should be defined 
(Figure 1). The strategic flow for a programme is 
indicated in Figure 2. 
Regardless of the health care system and 
its coverage, experience gained from national 
and local interventions should be brought 
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Figure 3: National asthma strategies for children and adults in countries responding to the Global 
Asthma Network survey, 2013.
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together. A major change for the better can be 
achieved by local efforts, systematic planning, 
and networking to implement the best possible 
asthma management practice. The gains can be 
remarkable, both in reducing human suffering 
as well as associated societal costs. The asthma 
burden can be tackled, and it is the responsibility 
of asthma experts and healthcare professionals to 
collaborate with national public health authorities 
and international organisations to improve 
efficiency in management and care.
Following in the successful footsteps of the 
Asthma Programme in Finland 1994-2004, an 
Allergy Programme 2008–2018 was launched 
there to combat the allergy epidemic, and to 
further assist the asthma epidemic. This new 
activity aims to increase immunological tolerance 
and improve management of severe allergy 
phenotypes, including asthma. The early results 
are promising and, in addition, economic costs for 
all allergy and asthma are declining. 
Global Asthma Network 
survey 2013-2014: national 
asthma strategies
A short survey for Global Asthma Network 
(GAN) centres was carried out in 2013. One of the 
questions was: “Has a national asthma strategy 
been developed in your country for the next five 
years? For children, for adults?” Of the 96 countries 
that answered, 25% had a programme for children 
and 23% had one for adults. Of the high-income 
countries (n=64), 34% reported a programme for 
children and 35% reported one for adults, while 
the corresponding figures were 20% and 17% 
for the low- and middle-income countries (n=32) 
(Figure 3 ). The details of the programmes are 
quite variable and would need further evaluation. 
Only a few countries have reported results of any 
nationwide, comprehensive programme. 
Conclusion
Generally, asthma responds favourably 
to effective drug treatment. The earlier the 
correct diagnosis is obtained, the better the 
response.  Patients should adhere to long-
term management, use inhalers correctly, and 
proactively prevent exacerbations by themselves 
after receiving education. In Europe, improved 
management has resulted in a remarkable 
decline in mortality (6287 asthma deaths in 1980 
and 1164 in 2012). Asthma mortality, however, 
is the tip of the iceberg when considering the 
overall asthma burden. Systematic national and 
regional asthma plans (programmes ) have been 
employed in many countries to tackle emergency 
visits, hospitalisations, disability, costs, and loss 
of productivity. When programmes involve 
community stakeholders and are tailored to 
the characteristics of the community, they work 
successfully. Benchmarking against specific 
indicators of asthma outcomes would improve 
implementation of best practices.
Health authorities in all 
countries should develop 
national strategies and action 
plans to improve asthma 
management and reduce costs.
Key Recommendation
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The role of guidelines
Asthma management guidelines play an 
important role in standardising timely and 
correct assessment of asthma symptoms and 
severity, and effective case management, thus 
potentially lessening the burden of asthma. More 
recently, asthma management guidelines have 
become evidence-based guidelines initiated by 
governments or non-profit bodies. In 2012 the 
World Health Organization (WHO) published 
guidelines for the management of asthma for 
children and adults in their report “Prevention 
and Control of Noncommunicable Diseases: 
Guidelines for primary health care in low resource 
settings.”
Key components of asthma guidelines are 
recommendations about what asthma medicines 
to use, and when to use them. It follows that 
the development of guidelines which are free 
of the influence, and thus potential bias, of 
the developers and manufacturers of asthma 
medicines (the pharmaceutical industry) is 
preferred. 
The Global Asthma Report 
survey 2011
Chapter 8 of the Global Asthma Report 2011 
reported a survey of asthma guidelines use in 
ISAAC centres. Of 92 countries responding (88% 
response rate), 74 countries (80%) used asthma 
management guidelines. Of these 74 countries, 
67 (73%) had their own national guidelines, 
45 (49%) used guidelines developed without 
support from the pharmaceutical industry, and 
31 (34%) had pharmaceutical industry support.  
Asthma management guidelines 
were first created in the 1980s, with 
many being commercially sponsored 
consensus statements.  Now, 
asthma management guidelines 
are most commonly   independent 
of pharmaceutical industry support 
and are evidence-based. The Global 
Asthma Report 2011 undertook the 
first worldwide survey on the use 
of National Asthma Management 
Guidelines and this survey was 
repeated by the Global Asthma 
Network (GAN) in 2013. Use of 
asthma management guidelines 
is increasing in countries around 
the world, particularly in low- and 
middle-income countries, and 
most of the guidelines in use 
were developed without financial 
assistance from the pharmaceutical 
industry.
9. Philippa Ellwood, Innes Asher, Karen Bissell, Guy Marks, Asma El Sony, 
Eamon Ellwood
Asthma Management 
Guidelines
Asthma management 
guidelines are an essential 
part of successfully 
managing asthma and 
promoting the delivery of 
quality asthma care.
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The Global Asthma Network 
survey 2013
In 2013, 105 GAN centres were asked to 
undertake a similar survey about asthma 
guidelines, completed on-line.  The survey 
questions are in Appendix A, Figure 6. The survey 
was completed by investigators in 96 countries 
(93%). Asthma management guidelines were 
used in 89% of the 96 countries (Figure 1). Most 
(63%) of the responding countries used their own 
national asthma guidelines.
The use of guidelines prepared with support 
of the pharmaceutical industry varied around 
the world (Figure 2). Of the 96 countries that 
completed the survey, 42% used guidelines 
sponsored by the pharamaceutical industry. 
Of the 63% of countries that had their own 
national guidelines, 15% were sponsored by the 
pharmaceutical industry, 30% did not provide 
information about whether pharmaceutical 
sponsorship was involved or not, and 8% used a 
combination of pharmaceutical sponsored and 
non-pharmaceutical sponsored guidelines (see 
Appendix A, Table 2 and Figure 7). 
Type of guideline
40% of countries used their own national 
guidelines exclusively. The Global Initiative 
for Asthma (GINA) guidelines (supported by 
unrestricted educational grants from non 
pharmaceutical and pharmaceutical companies) 
were exclusively used in 17% of countries, 7% 
used other international guidelines, and 25% of 
countries used several types of guidelines. 11% 
did not have any guidelines and, of these, 8% 
said they would use the recently released WHO 
guidelines and 3% did not intend to use the 
recently released WHO guidelines (Figure 1).
Use of guidelines in low-, 
middle-, and high-income 
countries
There were some different patterns of use 
of guidelines according to country income. 
Of the 96 countries, 32 (33%) were high-
income countries and 64 (67%) were low- and 
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middle-income countries. Exclusive use 
of their own national guidelines was 
greater in high-income countries than in 
low- and middle-income countries (78% 
and 55%, respectively). Use of GINA and 
other international guidelines was higher 
in low- and middle-income countries; The 
International Union Against Tuberculosis and 
Lung Disease (The Union) guideline was used 
in three of these. Of low- and middle-income 
countries, 11% intended to use the recently 
released WHO guidelines while only one 
high-income country intended to.  A similar 
proportion of low- and middle-income 
countries and high-income countries had 
similar figures for use of multiple guidelines, 
or no guidelines.
Time Trends
Most (72) countries participated in both 
the 2011 and 2013 surveys. Comparisons 
for some of the variables are shown in the 
Table.  The proportion of countries using 
guidelines increased over the two years, as 
did the number using multiple guidelines. 
Health authorities in all 
countries should ensure the 
availability of nationally 
appropriate asthma 
management guidelines, and 
provide access for everyone to 
the quality-assured, affordable 
essential asthma medicines 
those guidelines recommend.
Key Recommendation
Table: Comparison of 2011 and 2013 
asthma guideline usage for those 
72 countries participating in both 
surveys. 
2011 2013
Not using guidelines 14 (19%) 5 (7%)
Using guidelines 58 (81%) 67 (93%)
Using a national 
guideline
55 (76%) 52 (72%)
Multiple guidelines 1 (1%) 11 (15%)
Guidelines with no 
industry support*
31 (43%) 33 (46%)
Guidelines with 
industry support*
26 (36%) 35 (49%)
Guidelines with 
industry not 
specified
5 (7%) 10 (14%)
*Includes countries with multiple guidelines
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 Pharmaceutical sponsored guidelines
 Non-pharmaceutical guidelines
 Both pharmaceutical and non- 
 pharmaceutical guidelines
 Funding not specified
 No guidelines
 No response
 Not surveyed
Figure 2: Pharmaceutical sponsorship in asthma management guidelines in 
countries responding to the Global Asthma Network survey, 2013. 
The proportion of guidelines with specified 
pharmaceutical industry support increased from 
36% to 49%. This increase was in part caused by 
the number of countries using GINA guidelines 
increasing from 6 to 22 from 2011 to 2013. 
 Summary of surveys
These surveys fill a global data gap on 
guideline use by providers within countries. It is 
encouraging that the majority of countries use 
management guidelines, and that most of these 
were developed without financial assistance from 
the pharmaceutical industry.  Between 2011 and 
2013, our research suggests that the number of 
countries using a guideline has increased.  More 
than one guideline was used in one quarter of 
the countries. This is not surprising given the 
availability of guidelines through the internet. 
However guidelines which are not tailored to the 
health care system in the country where they are 
used will be more difficult to implement. 
 Most investigators were not aware of the 
recently released WHO guidelines, and at the 
time of the 2013 survey these guidelines were 
not widely used. They should be considered for 
primary health care in low-resource settings, 
especially where national guidelines free of 
pharmaceutical industry support are unavailable. 
Conclusion
National guidelines are an important tool 
for the management of asthma. International 
guidelines free of pharmaceutical industry 
support are freely available, including the WHO 
guidelines for low-resource settings. They can 
be used directly or, with permission, as a model 
for countries to modify for their own national 
guidelines. Guidelines should promote access for 
everyone to quality-assured, affordable essential 
medicines within the countries they are used.
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10. Access to Quality-Assured, 
Affordable Asthma Medicines
The World Health Organization (WHO) Essential 
Medicines List includes two inhaled corticosteroids 
(preventer inhalers) and one bronchodilator (a 
reliever inhaler) for asthma. A Global Asthma Network 
(GAN) survey shows that many countries do not 
have these WHO-recommended medicines on their 
national Essential Medicines List (EML), and many are 
not providing them free or subsidised for patients, 
especially in low-and middle-income countries. A 
number of medicine-related measures should be 
urgently addressed at a global and country level. 
Karen Bissell, Christophe Perrin
Figure 1: Essential asthma medicines survey 2014, Global Asthma Network countries.
(countries surveyed in blue)
Adding essential asthma 
medicines onto national Essential 
Medicines Lists and lists of 
reimbursed medicines will improve 
access to these medicines and 
reduce the burden of asthma.
Targets for essential asthma 
medicines 
WHO defines essential medicines as those 
that satisfy the priority health care needs of the 
population. They are intended to be available 
within the context of functioning health 
systems at all times in adequate amounts, in the 
appropriate dosage forms, with assured quality, 
and at a price the individual and the community 
can afford. An EML is a government-approved 
selective list of medicines that guides: the 
procurement and supply of medicines in the 
public sector; schemes that reimburse medicine 
costs; medicine donations; and local medicine 
production. When properly resourced, it is a 
cost-effective means of providing safe, effective 
treatment for the majority of communicable and 
non-communicable diseases.
The WHO EML includes two inhaled 
corticosteroids: beclometasone 50 micrograms 
(µg) and 100µg, and budesonide 100µg 
and 200µg, as well as one bronchodilator: 
salbutamol 100µg. Corticosteroids are called 
‘preventers’ because they act to prevent the 
chronic inflammation of the airways and 
reduce the twitchiness of the airways.  They 
are recommended for persistent asthma, and 
are effective at reducing the number of attacks 
and severity of asthma symptoms. They need 
to be taken once or twice a day every day even 
when a person is free of symptoms, and reach 
peak effect after two weeks. Bronchodilators are 
called relievers because they relieve the spasm 
of airway smooth muscle which occurs when 
asthma symptoms appear. Salbutamol starts to 
work straight after inhalation and reaches a peak 
of effect after 20 minutes which lasts for about 4 
hours. 
Patients with a chronic condition such as 
asthma need a reliable uninterrupted supply of 
quality-assured medicines. They also need to be 
able to afford these medicines over the long term, 
An 80% availability of the 
affordable basic technologies 
and essential medicines, 
including generics, required to 
treat major NCDs in both public 
and private facilities by 2025.
Source: World Health Organization (WHO) 
“Global monitoring framework and targets for 
non-communicable diseases (NCDs)”. 
WHO NCD TARGET  NUMBER 9
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Table:  
Inclusion of inhalers 
on the WHO Essential 
Medicines List 
(EML) in National 
EML and National 
Reimbursement Lists 
(NRL), by country, in 
99 Global Asthma 
Network countries, 
2014.
No   Not on list
Yes   Included on list 
n/a   No list
Beclometasone 
50 μg 
Beclometasone 
100 μg 
Budesonide  
100 μg 
Budesonide  
200 μg  
Salbutamol  
100 μg  
EML NRL EML NRL EML NRL EML NRL EML NRL
Australia n/a Yes n/a Yes n/a No n/a No n/a Yes
Austria n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
Belgium No Yes No No No No No Yes Yes Yes
Canada Yes Yes Yes Yes No No No No Yes Yes
Channel Islands Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Chile Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Croatia Yes Yes Yes Yes No No No No Yes Yes
Cyprus n/a No n/a Yes n/a No n/a No n/a Yes
Denmark No No Yes No No No Yes No No No
Faroe Islands Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Finland n/a Yes n/a Yes n/a No n/a No n/a Yes
France n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
French Polynesia n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
Germany n/a yes n/a Yes n/a Yes n/a Yes n/a Yes
Hong Kong n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
Ireland n/a Yes n/a Yes n/a No n/a No n/a Yes
Israel Yes Yes Yes Yes Yes Yes Yes Yes No No
Italy Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Japan Yes n/a Yes n/a Yes n/a Yes n/a Yes n/a
Korea, South Yes n/a Yes n/a Yes n/a Yes n/a Yes n/a
Kuwait Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Latvia No No No No No No No No Yes Yes
Malta n/a Yes n/a No n/a No n/a Yes n/a Yes
Netherlands n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
New Caledonia n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
New Zealand n/a Yes n/a Yes n/a No n/a No n/a Yes
Norway n/a Yes n/a Yes n/a No n/a No n/a Yes
Oman Yes n/a Yes n/a No n/a No n/a Yes n/a
Poland No No Yes Yes No No Yes Yes Yes Yes
Portugal No Yes No Yes No Yes No Yes No Yes
Reunion Island n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
Russia Yes Yes Yes Yes No No No No Yes Yes
Saudi Arabia Yes n/a No n/a No n/a Yes n/a Yes n/a
Singapore Yes Yes No No No No No No Yes Yes
Spain n/a Yes n/a No n/a Yes n/a Yes n/a Yes
Trinidad and Tobago Yes Yes Yes Yes Yes No Yes No Yes Yes
United Kingdom Yes Yes Yes Yes No No No No Yes Yes
United States n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Uruguay No n/a No n/a No n/a No n/a Yes n/a
Vatican City n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Albania Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Algeria No No No No Yes Yes Yes Yes Yes Yes
Argentina No No No No No Yes No Yes No Yes
Belarus Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Benin No n/a No n/a No n/a No n/a No n/a
Bosnia and Herzegovina No No No No No No No No Yes Yes
Brasil Yes No No No No No No No Yes No
Bulgaria Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Burkina Faso Yes No No No No No Yes No Yes No
Cameroon No n/a No n/a No n/a No n/a No n/a
China Yes Yes No No No No No No Yes Yes
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Beclometasone 
50 μg 
Beclometasone 
100 μg 
Budesonide  
100 μg 
Budesonide  
200 μg  
Salbutamol  
100 μg  
EML NRL EML NRL EML NRL EML NRL EML NRL
Colombia Yes n/a No n/a No n/a No n/a Yes n/a
Congo Dem Rep No n/a Yes n/a No n/a No n/a Yes n/a
Costa Rica No No Yes Yes No No No No Yes Yes
Ecuador Yes Yes Yes Yes No No No No Yes Yes
Egypt No No No No No No No No No No
Gambia No n/a No n/a No n/a No n/a No n/a
Ghana No No Yes Yes Yes Yes Yes Yes Yes Yes
Grenada Yes n/a Yes n/a No n/a No n/a Yes n/a
Hungary No No No No Yes Yes Yes Yes Yes Yes
India Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Indonesia No No No No Yes No Yes No Yes Yes
Iran Yes Yes No No Yes Yes Yes Yes Yes Yes
Jamaica Yes Yes Yes Yes No No Yes Yes Yes Yes
Jordan Yes Yes Yes Yes No No No No Yes Yes
Kenya No n/a No n/a No n/a No n/a No n/a
Kosovo No No No No No No No No Yes No
Lao PDR No No No No No No No No Yes No
Macedonia Yes Yes No No No No Yes Yes Yes Yes
Malawi Yes n/a Yes n/a No n/a No n/a Yes n/a
Malaysia No n/a Yes n/a Yes n/a Yes n/a Yes n/a
Mexico No Yes No Yes Yes Yes Yes Yes Yes Yes
Mongolia Yes No Yes No No No No No Yes Yes
Nicaragua Yes Yes Yes Yes No No No No Yes Yes
Nigeria Yes n/a No n/a No n/a No n/a Yes n/a
Pakistan No n/a No n/a No n/a No n/a No n/a
Palestine No n/a No n/a No n/a Yes n/a Yes n/a
Panama Yes Yes No No No No Yes Yes Yes Yes
Philippines Yes Yes Yes Yes No No Yes Yes Yes Yes
Romania Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Samoa No No Yes No No No No No Yes No
Senegal No No No No No No No No No No
Serbia Yes No Yes Yes Yes No Yes Yes Yes Yes
South Africa Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Sri Lanka Yes n/a Yes n/a No n/a No n/a Yes n/a
Sudan Yes No No No No No No Yes Yes Yes
Syrian Arab Republic No Yes No Yes No Yes No Yes Yes Yes
Taiwan n/a No n/a No n/a No n/a Yes n/a Yes
Thailand Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Togo Yes Yes Yes Yes No No No No Yes Yes
Tokelau Yes n/a No n/a No n/a No n/a Yes n/a
Tonga No n/a Yes n/a No n/a No n/a Yes n/a
Tunisia Yes Yes No No No No No Yes Yes Yes
Turkey n/a Yes n/a Yes n/a Yes n/a Yes n/a Yes
Tuvalu Yes n/a Yes n/a No n/a No n/a Yes n/a
Uganda Yes n/a No n/a No n/a No n/a Yes n/a
Vietnam No No No No No No No No Yes Yes
Zambia Yes n/a No n/a No n/a No n/a Yes n/a
Zimbabwe Yes n/a Yes n/a No n/a No n/a Yes n/a
Total (Yes) n=99 49 50 42 46 24 31 33 42 68 64
Total (Yes) % 49% 51% 42% 46% 24% 31% 33% 42% 69% 65%
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not just for a one-time or short-term expenditure 
as for many communicable diseases. To provide 
for these patients, countries need to add essential 
asthma medicines onto national EMLs and/or 
reimbursement lists. Global targets have been 
established by WHO  to encourage countries to 
improve access to quality-assured, affordable 
medicines for non-communicable diseases, 
including asthma (see Box), and GAN has created 
specific targets for asthma (see Chapter 1).
Global Asthma Network 
survey about essential 
asthma medicines 2014
GAN Principal investigators were surveyed in 
May 2014 with a brief questionnaire about the 
inclusion of WHO essential asthma medicines in 
two lists their countries may have: a national EML 
and a type of national reimbursement list (NRL) 
or similar, which lists medicines that are either 
fully or partially reimbursed by the government. 
Data were returned from 99 of 118 countries 
surveyed. The results are presented in the Table, 
with countries grouped as high-income countries 
(HICs) or low- and middle-income countries 
(LMICs). Results presented here should not be 
considered definitive. Some results may reflect 
a difficulty for health services to access and 
interpret information about these lists; some 
results would benefit from explanations about the 
specificities of individual health systems. Mostly, 
however, the outcome for the patient is the same 
– if the essential medicines they need have not 
been prioritised at national level, the patients 
will have difficulty accessing them and affording 
them. 
Of the 99 responding countries, 79 (80%) 
have an EML, with an impressive 57 (97%) of 
the LMICs having an EML. However, the results 
show that the asthma medicines on WHO EML 
are not systematically included by all countries 
in their EMLs. Of the 79 countries that reported 
having an EML, 62 (78%) had one or more 
inhaled corticosteroid on their EML, and 68 
(86%) had the bronchodilator salbutamol on 
their EML. However, a range of doses of inhaled 
corticosteroid is needed so that the appropriate 
dosage can be prescribed, for each level of 
disease severity. It is therefore of concern that 
only 16 (40%) HICs and 33 (56%) LMICs have 
the corticosteroid beclometasone 50µg on their 
EML, and only 16 (40%) HICs and 26 (44%) LMICs 
have beclometasone 100µg. The inclusion of 
budesonide was even lower: 9 (23%) HICs and 15 
(25%) LMICs had the 100µg dosage; 12 (30%) HICs 
and 21 (36%) LMICs had the 200µg. 
Of 73 countries that reported having a 
National Reimbursement List (NRL), 60 (82%) 
had one or more inhaled corticosteroid on the 
NRL. There was a marked difference between 
country income level regarding inclusion of 
corticosteroids on the NRL: 31 (94%) of the HICs 
versus 29 (73%) of the LMICs. There were 28 (70%) 
HICs but only 21 (36%) LMICs that included 50µg 
beclometasone; similarly, 27 (68%) HICs but only 
19 (32%) LMICs included 100 µg beclometasone. 
Best reimbursed was salbutamol: 64 (88%) of the 
countries with an NRL included it; 31 (78%) of 
the HICs and 33 (56%) of the LMICs. Patients in 
HICs with some kind of national reimbursement 
scheme for improving access to medicines are 
faring best – for HICs with an NRL, 94% included 
both an inhaled corticosteroid and salbutamol. 
In conclusion, although countries may have 
other dosages or formulations of these medicines, 
and other asthma medicines, in circulation, this 
survey shows that many countries do not have the 
WHO-recommended essential asthma medicines 
on their lists, and many are not providing them 
free or subsidised for patients, especially in LMICs. 
This situation is detrimental for patient access 
to medicines. It requires urgent attention and 
ongoing monitoring. 
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Measures to improve access 
People often speak about high prices being 
a barrier to accessing medicines. However, 
there are in fact many factors that can affect the 
availability and affordability of quality-assured 
essential asthma medicines. Countries may need 
to work on how asthma medicines are addressed 
in their national policies, programmes, guidelines, 
budgets and teaching curricula, for example, as 
well as how medicines are procured and made 
available to patients. The following measures 
would improve access to quality-assured 
medicines:
1. Include the essential asthma medicines 
in national EMLs and NRLs, and stop 
reimbursing inappropriate, unnecessary, 
and very expensive asthma medicines.
2. Ensure EMLs and NRLs include products 
only propelled by hydrofluoroalkanes 
(HFA) , and that product strengths have 
been updated where appropriate (HFA 
propellants replaced chlorofluorocarbons, as 
required by the 1987 Montreal Protocol on 
Substances that Deplete the Ozone Layer). 
3. Check that national asthma management 
guidelines are based on medicines that 
are available and affordable, and that the 
guidelines explicitly address the need to 
ensure access to medicines at all levels of 
health care, and especially among poor and 
marginalised populations. 
4. Add essential asthma medicines to the list 
of the WHO Prequalification Programme (a 
centralised quality assessment initiative that 
has achieved greater access for millions of 
patients to quality-assured medicines for 
selected diseases). 
5. Standardise the dosages of active 
ingredients in combined inhalers marketed 
in both high- and low- and middle-income 
countries to facilitate quality assessment, 
procurement, prescribing practices and the 
achievement of affordable prices globally 
(see chapter 11 for more).
6. Harmonise quality requirements across the 
international reference documents such 
as the pharmacopoeias (see chapter 11 for 
more).
7. Facilitate the development of independent 
laboratories for the testing of generic 
products that are not already approved by 
a stringent regulatory authority or relevant 
global mechanism.
8. Encourage low- and middle-income 
populations to demand quality-assured, 
affordable essential medicines for asthma 
as part of the health care provided by the 
government.
9. Support in-country implementation of 
sustainable cost recovery programmes 
such as Revolving Drug Funds (after an 
initial capital investment, medicine supplies 
are replenished with monies collected 
from the sales of medicines). Such funds 
become self-financing and build demand for 
quality-assured, affordable essential asthma 
medicines. 
10. Monitor and strengthen country capacity in 
pharmaceutical policy and procurement.
11. Monitor and publish on factors that 
influence availability, affordability, and 
access to essential asthma medicines.
Conclusion
Most countries have not included the essential 
medicines recommended by the WHO on their 
EMLs and most do not reimburse these asthma 
medicines. The main type of asthma preventer 
medicines which lead to improved asthma 
control (inhaled corticosteroid inhalers) are less 
commonly supported by governments than the 
short term reliever inhaler, even though reliance 
solely on the reliever does not reduce the burden 
of asthma in the long term (see chapter 12). 
Governments in all countries 
should ensure that they have 
a list of essential medicines for 
asthma which includes both 
inhaled corticosteroids and 
a bronchodilator in dosages 
recommended by WHO, and 
that these are available, quality-
assured, and affordable for 
everyone in their countries.
Key Recommendation
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Asthma inhalers are among the 
most complex pharmaceutical 
industry manufactured medical 
devices in widespread use. To be 
safe and efficacious, they need 
to comply with international 
quality standards. Inhalers of the 
original brand (innovator) and 
subsequent products produced by 
different manufacturers (generics) 
may meet these standards, but 
many asthma inhalers in the 
marketplace do not. Low-resource 
settings would benefit greatly if 
the World Health Organization 
(WHO) Prequalification 
Programme could include 
essential asthma medicines and 
provide its technical support 
to countries. WHO should 
promote standardised dosages 
for combination inhalers 
and harmonise the quality 
requirements for inhalers across 
all the international reference 
pharmacopoeias. 
Inhalers are complex devices
Asthma inhalers, also called ‘pressurised 
Metered Dose Inhalers’ (pMDI), are among the 
most complex medical devices manufactured by 
the pharmaceutical industry. Active ingredients, 
such as salbutamol or beclometasone, are mixed 
with a propellant in a canister. When a person 
presses upwards on the actuator, a standardised 
dose of the active ingredients is pushed by the 
metering valve into the mouthpiece (Figure 1). 
The person then inhales the active ingredients 
into his/her airways, where they should stay 
and thus be “deposited”. Children, the elderly, 
and others who have trouble coordinating their 
movements, should always use pMDI with a 
spacer or holding chamber attached to optimise 
delivery of the aerosol into the lungs.
It is important that a high deposition rate 
is achieved in the lungs and the periphery 
of the lungs, and that as little medication as 
possible deposits in the mouth or throat, or gets 
swallowed into the gastrointestinal tract. This is so 
the active ingredients can achieve the intended 
effect on the airways (reliever or preventer). For 
these reasons, the amount deposited in the lung 
(pulmonary deposition rate) of a pMDI needs 
to be measured against internationally agreed 
standards of efficiency and safety. For adults, the 
particles of the active ingredient have to be less 
than 5 micrometres in order to travel efficiently 
into the patient’s lungs. Only particles between 1 
and 3 micrometres will manage to be deposited 
deep in the lungs. Particles of less than 0.5 
micrometres are automatically exhaled and thus 
have no effect. In children, and particularly in 
infants and preschoolers, the “breathable” particle 
size is considerably lower. 
Both innovator and 
generic products have met 
international standards 
A further key requirement for inhalers is to 
deliver the same quantity of active ingredients 
(e.g. 100 micrograms of salbutamol) for each of 
the 200 doses contained in a canister. The fine 
particle size distribution in the puff, or cloud of 
the spray, has to conform to strict calibration 
11.
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curves that will allow efficient deposition in the 
lungs. Manufacturing hundreds of thousands of 
pMDIs that conform to these strict requirements, 
batch after batch, year after year, represents a 
significant technical challenge for pharmaceutical 
companies. It is no surprise then that only a 
limited number of manufacturers worldwide have 
the capacity to produce innovator or generic 
pMDIs that meet international quality standards.  
Furthermore, there is a wide variability in the size 
of the particles in an aerosol generated by pMDIs 
made by different manufacturers, even for the 
same medication (e.g. for budesonide). Therefore, 
manufacturers should be required to specify 
particle size distribution, so that clinicians can 
correctly select the best aerosol for each patient.
Nevertheless, innovator and generic single 
ingredient pMDIs supplied by manufacturers 
based in the United Kingdom, Spain, India, and 
Bangladesh have successfully gone through three 
consecutive qualification processes conducted 
by the Asthma Drug Facility (ADF) (a project of 
The Union) between 2008 and 2013, after public 
and international invitations for Expressions 
of Interest. These qualifications were based on 
international quality standards set by the WHO 
and stringent National Medicine Regulatory 
Agencies (NMRAs). In addition, generic companies 
have started to register some of their pMDIs with 
stringent NMRAs, such as the NMRA in the United 
Kingdom. 
Despite the challenge for generic companies 
to develop a formulation with the required 
characteristics, as well as to define the right 
combination of diameters of the metering valve 
and the actuator nozzle to dispense the right size 
of fine particles, several of them have managed 
to demonstrate the bio-equivalence of their 
generic products with innovator products. Bio-
equivalence means the efficiency and safety of 
a generic medicine is the same as that of the 
innovator product and is in compliance with 
international quality standards. It is one of the 
fundamental requirements for generics. 
In all countries, an NMRA is responsible for 
ensuring the quality of medicines marketed 
on their territory. However, according to WHO 
surveys, 30% of NMRAs, principally those in 
low-income countries, have limited capacity 
to perform regulatory functions and 50% have 
variable capacity to do so, whereas stringent 
NMRAs are found mainly in wealthier countries. 
Thus, many NMRAs have major difficulty assessing 
the innovator and generic pMDIs they want to 
supply to their populations. This may lead to some 
treatment failure and/or safety issues.
International measures to 
support countries 
Considering the great global burden of 
asthma, and that effective medicines for it are 
available, having quality-assured effective asthma 
pMDIs is vital. An important step is to have pMDIs 
added to the WHO Prequalification Programme, 
which is a centralised quality assessment initiative 
capable of qualifying products which meet the 
strict technical criteria discussed above. Since 
2001, the centralised quality assessment of 
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Pressurised metered dose 
inhaler.
medicines for HIV/AIDS, tuberculosis, malaria 
and reproductive health has achieved greater 
access for millions of patients to quality-assured 
medicines for these diseases, even in the least 
affluent countries. If asthma pMDIs were added 
to the list, the WHO Prequalification Programme 
could provide technical assistance to NMRAs in 
how to assess the inhalers, as well as guidance 
for manufacturers in how to upgrade their 
production of asthma inhalers.
The WHO could also contribute to improving 
the quality of pMDIs circulating globally by 
promoting the standardisation of the dosages 
of active ingredients in combined inhalers 
that are marketed in both high- and low- and 
middle-income countries.  Combined inhalers 
are made of a bronchodilator (short or long 
acting β2 agonists) and a corticosteroid. Together 
they reverse the inflammation in the lungs 
and have a bronchodilatory (airway-opening) 
effect. However, there is great variation in the 
dosages available globally today, especially those 
including long acting β2 agonists. Such variation 
is not justified by objective clinical data and 
creates unnecessary confusion for prescribers, 
dispensers, patients, and their families.
It would also be greatly beneficial if WHO 
could promote the harmonisation of quality 
requirements across current international 
references, such as the pharmacopoeias (reference 
books containing directions for the identification 
of compound medicines) of the United States, 
the United Kingdom and Europe. These would 
assist the pharmaceutical industry and NMRAs 
by having clearer quality standards to work with 
for the production and assessment of pMDIs. In 
addition, WHO should modify the requirements 
for becoming a WHO-prequalification laboratory. 
These should include the ability to analyse 
particle size distribution using a cascade 
impactor. If WHO-prequalified laboratories could 
provide this service, complemented by a network 
of qualified university-based laboratories that 
specialise in analysing aerosols, then NMRAs from 
low- and middle-income countries would have 
independent places to test any generic products 
not already approved by a stringent regulatory 
authority or a global mechanism such as an 
Asthma Drug Facility. 
Conclusion
The manufacture of asthma inhalers requires 
accuracy and reliability so that their quality is 
assured for each dose, and from one inhaler to 
another. Non-quality-assured asthma inhalers 
may be ineffective.
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The WHO should add essential 
asthma medicines to their 
Prequalification Programme, 
promote the standardisation 
of the dosages of active 
ingredients in combined 
inhalers and the harmonisation 
of quality requirements for 
inhalers across international 
reference documents such as the 
pharmacopoeias. Governments 
in all countries should ensure 
all asthma inhalers procured, 
distributed, and sold in their 
countries meet international 
quality standards.
Key Recommendation
Asthma Management 
in Low-Income 
Countriesx12.
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Low-income countries face extra 
challenges to achieve good asthma 
management compared with other 
countries. They have more difficulty 
achieving an uninterrupted supply of 
quality-assured, affordable essential 
asthma medicines, well-trained 
health professionals, well-organised 
health services to provide long-term 
care, standardised management 
of asthma with appropriate use 
of inhaled corticosteroids, and 
information systems for monitoring 
and improving quality of care. To 
achieve all these vital components 
of asthma care, commitments are 
needed from governments, and such 
commitments may be harder to achieve 
where resources are scarce, making 
the contributions of national non-
governmental organisations (NGOs) and 
global governmental agencies such as 
the World Health Organization (WHO) 
vital. 
Goals for successfully managed asthma
The goals for successfully managed asthma (Chapter 8) are the same in low- as 
in middle- and high-income countries – people with asthma will have minimal 
symptoms and minimal side effects of any medicines, and have no limitations on 
their lifestyle due to asthma. 
Inhaled corticosteroids are essential to success
Inhaled corticosteroids (asthma preventer medicines) are essential for 
achieving these goals and managing patients with persistent asthma over the 
long term. However, studies in low-income countries have found that health care 
workers often don’t prescribe inhaled corticosteroids for asthma. When they do 
prescribe them, patients often abandon them and rely on bronchodilators (reliever 
medicines) instead. 
Patients may be inclined to believe that bronchodilators are effective 
because these medicines provide quick relief from symptoms and that inhaled 
corticosteroids are not effective because they observe no immediate, obvious 
effect from them. These beliefs are understandable, and common in people 
throughout the world, resulting in the need for active asthma education as part 
of good asthma care. In low-income countries where these medicines are less well 
known, the education task is harder. Further, in low-income countries the cost of 
inhaled corticosteroids is usually much higher than bronchodilators and may not be 
affordable. Consequently patients are likely to over-use bronchodilators and under-
use inhaled corticosteroids. 
Karen Bissell, Chiang Chen-Yuan, Nadia Aït-Khaled, Christophe Perrin
Asthma can be effectively and 
affordably managed in low-
resource countries. In 2012 
WHO published guidelines for 
asthma management in low-
income settings.
Projects undertaken with the International 
Union Against Tuberculosis and Lung Disease 
(The Union) in  Benin and Sudan evaluated 
asthma treatment outcomes after one year of 
follow-up. They found that asthma severity and 
symptom frequency reduced significantly when 
patients took preventer treatment regularly. 
However there were challenges: practitioners 
demonstrated only moderate adherence to 
guidelines when grading the severity of their 
patients’ asthma and prescribing inhaled 
corticosteroids. A substantial proportion of 
patients also stopped taking their inhaled 
corticosteroids. 
What is needed to manage 
asthma effectively in 
low- and middle-income 
countries?
The under-use of inhaled corticosteroids 
is resulting in inadequate asthma control, 
frequent unplanned visits to the emergency 
room or hospitalisations, and an unnecessary 
reduction in quality of life for those who live 
with asthma which, in low-income countries, 
places a disproportionate burden on the people 
with asthma and society at large. There are 
several reasons for the failure of health systems 
to provide appropriate asthma care. To turn this 
situation around requires action on several fronts:
Countries need to apply guidelines for 
standard case management of asthma 
The term ‘standard case management’ 
encompasses diagnosis of asthma, 
standardisation of treatment according to 
severity based on asthma guidelines, and patient 
education, coupled with a simple system for 
monitoring patient outcomes. Appropriate 
training of health care workers and availability 
of essential asthma medicines are key to the 
effectiveness of standard case management. The 
Union’s asthma guidelines were pilot-tested in 
health centres in Algeria, Guinea, Ivory Coast, 
Kenya, Mali, Morocco, Syria, Turkey, and Vietnam. 
Investigators concluded that the measures were 
feasible, effective, and cost-effective. In four 
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recent asthma projects that involved The Union, 
in Benin, China, El Salvador and Sudan, the 
training of clinicians in guideline implementation 
and outcome evaluation was combined with the 
procurement of affordable essential medicines 
for asthma. All countries observed a substantial 
reduction in the severity of asthma for the 
majority of enrolled patients and the almost 
complete disappearance of visits to emergency 
services and hospitalisations in patients that were 
adhering well to treatment. 
Clinicians and health care workers 
need to be trained to identify asthma 
patients
In Huaiyuan County, Anhui Province, China, a 
project with The Union revealed that asthma was 
not being diagnosed in the participating facilities 
before the project was introduced. Patients 
presenting with cough and difficult breathing 
were usually diagnosed with chronic bronchitis 
and treated with a combination of antibiotics, 
systemic steroids, xanthine derivatives and/or oral 
β-2 agonists. 
Inhaled corticosteroids had never been 
available prior to the project. After training, 
health workers identified a substantial number of 
asthma patients who were treated with inhaled 
corticosteroids and inhaled salbutamol. What this 
project suggested was both that asthma may be a 
hidden disease in rural China and that it is feasible 
to train health workers to provide standardised 
case management of asthma. 
Quality-assured essential asthma 
medicines need to be accessible and 
affordable to all who need them
In low-income countries, essential asthma 
medicines are more likely to be unavailable than 
in more affluent countries (see Chapter 10). They 
are more likely to be of inadequate quality (see 
Chapter 11) due to inadequate government 
regulation. They are also more likely to be 
unaffordable, in that an inhaled corticosteroid 
inhaler may cost as much as the equivalent of 
two weeks wages. Such high costs are a major 
obstacle to the person with asthma receiving the 
medicine they need.  
A situation analysis in Benin prior to the 
project there revealed that only 11% of asthma 
patients were prescribed inhaled corticosteroids. 
In both El Salvador and Sudan, inhaled 
corticosteroids were not available in the pilot 
sites before the project. The Union, through its 
Asthma Drug Facility (ADF) 2008-2013, worked 
with several countries running pilot projects 
which demonstrated that the price of essential 
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asthma medicines could be markedly reduced 
through negotiation with suppliers of quality-
assured medicines so that they could be procured 
at affordable prices.  In Benin, the price of the 
inhaled corticosteroid beclometasone was €4.27 
per inhaler before this process and was reduced 
to €1.98 when procured through the ADF. Similar 
price reductions were achieved for El Salvador 
and Sudan.  Benin also established a financial 
mechanism to ensure an uninterrupted supply 
of essential medicines for asthma. Known as a 
Revolving Drug Fund, this mechanism works 
because, after an initial capital investment, 
medicine supplies are replenished with monies 
collected from the sales of medicines. Such 
funds become self-financing and build demand 
for quality-assured, affordable essential asthma 
medicines. 
Health services need to serve chronic 
patients effectively
In many low-income countries the huge 
majority of asthma patients are only being treated 
on an emergency basis – when they arrive in the 
emergency department with an acute attack of 
asthma. Health services need to be organised 
for the long-term management of asthma, with 
trained health care workers and regular follow-up 
of patients. This will reduce emergency visits and 
hospitalisations, and empower patients and their 
families to manage their asthma. 
Collecting and monitoring data helps 
to assure quality of care
Information systems are less likely to be well 
developed in low-income countries than in more 
affluent countries. To evaluate the effectiveness 
and quality of asthma care, an information system 
allowing outcome assessment of registered 
asthma patients and overall evaluation of asthma 
management should be established for facilities 
providing care. 
Patient education is needed to 
overcome fears and encourage self-
management
Patient education is essential to prevent 
unnecessary concerns about asthma and asthma 
medicines, especially in low-income countries 
where there has been little experience with 
asthma. Patients need to learn that inhaled 
corticosteroid inhalers are not addictive or 
dangerous. They need to understand that their 
condition is ongoing, possibly lifelong, and 
that it is variable (i.e. the timing and extent of 
symptoms varies). They also need to learn how to 
manage their asthma: how and when to take their 
medicines and when to seek help from health 
care facilities.
Governments need to help set up long-
term management of asthma
An uninterrupted supply of quality-assured, 
affordable essential asthma medicines, organised 
services and trained human resources are the 
minimum requirements for the health services 
to manage asthma. These are harder to achieve 
in low-income countries. Political commitment 
is critical for establishing and maintaining the 
long-term management of asthma, especially in 
resource-limited settings.
Conclusion
In low-income countries, where asthma is 
not as well recognised and effective asthma 
management has not been commonplace, 
carefully planned programmes can be introduced 
to improve management. The components 
include access to quality-assured essential asthma 
medicines, asthma management guidelines, 
health service organisation, patient education and 
political commitment.
Governments in low-income 
countries should make 
commitments to ensure that 
the supply of quality-assured, 
affordable essential asthma 
medicines is uninterrupted, 
health professionals are 
appropriately trained, and 
health services are organised to 
manage asthma.
Key Recommendation
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Brief History
The Global Asthma Network (GAN), 
established in 2012, brought together 
a global network of asthma researchers 
from the International Study of Asthma 
and Allergies in Childhood (ISAAC) and the 
International Union against Tuberculosis 
and Lung Disease (The Union).  Over the 
years, ISAAC and The Union have provided 
many opportunities for further research 
collaboration and training. In many instances 
this has involved researchers from low- and 
middle-income countries doing a higher 
degree (e.g. MPH, MSc, PhD) in universities in 
high-income countries. However, this is often 
not an option because of the cost and time 
involved. Short courses in research generally, 
or asthma research in particular, provide 
opportunities for ‘upskilling’ in research for 
those with limited time and resources.
Typical courses, who 
should go and why 
Typical short courses on asthma research 
and policy range from one to three weeks, 
and may include a range of clinicians, 
epidemiologists, public health professionals, 
statisticians, and professionals from other 
disciplines. The opportunity to interact with 
researchers from other disciplines and with 
other interests is often a strength of such 
short courses. They may also involve a range 
of levels (PhD students, post-doctoral fellows, 
and more experienced researchers who 
need a ‘refresher’) and may include lectures, 
exercises, discussion sessions, and practical 
experience in the design of a research 
proposal.
Some recommended 
courses
There are many such short courses available 
in different parts of the world. Some highly 
recommended courses in which GAN Steering 
Group members are involved include:
• The European Educational Programme 
in Epidemiology; this is a three-week 
residential course which has been held 
every June/July in Florence since 1990 
(www.eepe.org/).
• The International Epidemiological 
Association International Course on 
Epidemiological Methods; this is a two-
week residential course which has been 
held every April/May in various parts of 
the world since 2009 (www.iea-course.
org/).
• Operational research courses conducted 
by The Union; participants design their 
own research questions and are guided 
through the research process right 
through to preparing a paper to report 
the results. These Operational Research 
courses are made up of 3 one week blocks 
of course work which are spread out over a 
time period of 10 months (www.theunion.
org/).
• Issues in Global Non-communicable 
Disease: From Research to Policy; this is 
an annual one week course run in London 
by the London School of Hygiene and 
Tropical Medicine Centre for Global Non-
communicable Disease. It integrates 
research and policy for NCDs in general, 
including asthma (www.lshtm.ac.uk/
study/cpd/issues_ncd.html).
13. Neil Pearce, Nils Billo, Karen Bissell
Short Courses 
Relevant to Asthma 
Research and Policy
Health authorities in all 
countries should encourage their 
health professionals to attend 
short courses relevant to asthma 
research and policy.
Key Recommendation
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PART THREE:   
ASTHMA - 
A GLOBAL 
PRIORITY
Monitoring asthma 
in populations will 
lead to better 
outcomes for 
people with 
asthma.
14. Asma El Sony , Nadia Aït-Khaled, Javier Mallol  
Asthma is already an  
epidemic
 It is concerning that the global burden of 
asthma, which is already substantial in terms 
of both morbidity and economic costs, seems 
to be increasing rapidly as the world becomes 
more westernised. Low- and middle-income 
countries shoulder most of the asthma-related 
deaths.  The recent Global Burden of Disease (GBD)
study estimated that asthma was the 14th most 
important disorder in terms of global years lived 
with disability. Therefore when assessing health 
priorities, allocating resources, and evaluating 
the potential costs and benefits of public health 
interventions, asthma should be among the 
top priorities of Ministries of Health in low- and 
middle-income countries. 
Underprivileged settings and 
fragile health systems are 
characteristics of Low- and 
Middle-income countries
Within low- and middle-income countries 
poverty has a larger effect on the quality of life of 
communities, and on health system preparedness 
for disease, compared with high-income countries. 
Poverty is a vicious cycle that may deprive people 
of their basic human rights. Poverty affects both 
systems and people: it constrains education 
and health systems as well as people’s ability 
to seek education and health care. Poverty 
also exacerbates risk factors, such as indoor 
air pollution and tobacco consumption, and 
increases the burden of communicable and non-
communicable diseases. 
Asthma as a Lung Health 
Priority in Low- and 
Middle-Income Countries 
It is essential that asthma becomes 
an explicit global health priority, 
alongside and complementary 
to other non-communicable 
diseases (NCDs) including chronic 
obstructive pulmonary disease 
(COPD), and lung infections such 
as pneumonia and tuberculosis.  
Asthma, because it causes such 
a burden of disease, should 
be one of the top priorities of 
governments, development 
partners and partners in lung 
health, yet at the present time 
it has little profile with them. 
We must accelerate our efforts 
to overcome the operational 
bottlenecks that are preventing 
patients from receiving care 
in low-income settings. 
Implementing standard case 
management (see Chapter 12), 
strengthening health systems 
at all levels, starting from the 
community level, and using 
appropriate technologies 
efficiently are the way to go.  
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How far are we from welfare 
and equity? 
Access to and affordability of asthma 
management and control:
Disparities in health coverage within low- 
and middle-income countries are huge and 
expenditure on health and development is 
generally very low. Barriers to accessing health 
services are many, so when combined with the low 
coverage of health insurance, families may face 
catastrophic out-of-pocket expenditure when a 
family member has asthma. Absence of guidelines 
(see Chapter 9) and non-standardisation of 
asthma management increases the cost and has 
the potential to force families into poverty due 
to direct and indirect costs to themselves.  This 
can lead to disastrous events for individuals and 
society - children may be stopped from attending 
school so that their treatment can be purchased 
and breadwinners may be unable to work on their 
farms and feed their families because of severe 
asthma symptoms. 
In low- and middle-income countries, there 
are various operational bottlenecks facing asthma 
management and control. The reasons for these 
include: a lack of consensus around asthma as a 
priority; lack of training of health care workers; 
lack of patient education in chronic disease 
management; lack of diagnostic equipment 
such as peak flow meters and mouthpieces; lack 
of access to essential asthma medicines; the 
high cost of these inhalers and delivery devices 
(holding chambers or spacers); and the effect of 
international agreements such as Trade-Related 
aspects of Intellectual Property Rights (TRIPS) 
on the costs of, and access to, essential asthma 
inhalers. 
These problems can be addressed successfully. 
For example, studies in 2007-8 in Sudan (Figure 1) 
and Benin (Figure 2) trained health workers and 
delivered standard case management of asthma. 
Among patients present at the one year follow-up 
visit, 50% improved in Benin and 82.6% improved 
in Sudan, with a huge reduction in emergency 
room visits and economic costs. 
Asthma and Stigma:
Asthma symptoms, especially breathlessness, 
can cause fear and other psychological and 
emotional suffering. Stigma within communities 
is noticeable; it can delay health seeking and case 
detection, and it hinders adherence to long-term 
management. 
The stigma hinders everyday life including 
the ability to socialise. In some places there is a 
reluctance to marry a person with asthma to avoid 
passing the disease on to future offspring. Some 
refuse to use preventive inhalers as they see it as 
a declaration of having asthma for the rest of their 
life. 
Slow progress getting asthma high on 
the political agenda:
The High Level Meeting of the 66th Session 
of the United Nations General Assembly held in 
September 2011 issued a Political Declaration that 
focused the attention of world leaders and the 
global health community on the prevention and 
control of NCDs. Asthma is included in the global 
NCD agenda under “chronic respiratory diseases”, 
Asthma is a serious 
burden in low- and 
middle-income 
countries and we should 
accelerate efforts to 
make asthma a lung 
health priority. Asthma 
management and 
control is feasible and it 
should be on everyone’s 
agenda.
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Figure  1: The reduction in 
emergency room visits from 
one year of enrolment in 
the asthma standard case 
management project in 
Sudan 2007-08.
Figure 2: Number of emergency 
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Benin: initial at enrolment 
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Governments in low- and 
middle-income countries should 
make asthma a health priority, 
in order to more quickly invest in 
asthma research relevant to their 
populations, integrate care at 
community and primary health 
care levels with appropriate 
referral procedures, and develop 
capacity in standard case 
management of asthma.
Key Recommendation
yet the proposed interventions will do little to 
prevent or control it - unless the declaration 
is backed-up with national and international 
political commitment, support and resources.
Following the Declaration, low- and middle-
income countries committed themselves to 
developing national action plans to control 
these chronic conditions. However, strategic and 
collaborative action has been slow. Technical 
and financial assistance should be given to low- 
and middle-income countries so that they can 
build a responsive health infrastructure, capable 
of tackling the physical, social and economic 
conditions that affect the burden of asthma on 
their populations. 
Efforts should be speeded up 
collectively by:
• Investing in research to measure asthma 
trends in relation to geographic location, 
socio-economic status and marginalised 
populations.
• Developing pro-poor strategies in which 
asthma is a “lung health priority” and 
developing guidelines that integrate asthma 
care at community and primary health care 
levels.
• Developing the capacity of human resources 
to diagnose and manage asthma, through 
standardised case management, and to 
respond to patients’ needs.
• Procuring a regular supply of quality-assured, 
affordable asthma medicines and equipment 
through a regular supplier that is linked to 
an asthma management programme (see 
Chapters 10 and 12)
• Strengthening referral procedures for asthma 
patients within the health system.
• Adopting The Union’s innovative application 
of the Directly Observed Treatment Short-
course (DOTS) strategy for treatment of 
tuberculosis in the community in low- and 
middle-income countries to asthma and lung 
health. Integrating asthma management with 
DOTS has already shown success in improving 
treatment outcomes and reducing the burden 
of asthma in resource-poor settings. 
• Strengthening community systems, such as 
informal health providers, in order to increase 
access to care and case detection, and to 
reduce stigma.
• Establishing “patients networks” to empower 
patients as central partners in the efforts to 
manage asthma and to advocate for greater 
political commitment. 
• Utilising innovations and appropriate 
technologies in a sustainable manner to 
support standard case management; by 
improving awareness, case detection, 
adherence and long-term follow-up. For 
example, a Sudan pilot project using rapid 
mobile asthma Short Message Service 
(SMS) texts showed that such SMS use was 
feasible, reduced rates of loss to follow up, 
and supported standard case management 
by improving awareness, case detection, 
adherence, and long-term follow-up. 
Conclusion
Asthma has a low profile in the health 
priorities of low- and middle-income countries. 
The identification of asthma as a lung health 
priority would give it attention along with COPD, 
pneumonia, and tuberculosis.
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Asthma as an NCD 
Priority  
The asthma epidemic 
experienced by high-income 
countries over the past 30 years 
is now an increasing problem 
in low- and middle-income 
countries as they become more 
urbanised. Non-communicable 
diseases (NCDs) are emerging 
as a major global public health 
problem and asthma is an 
important component of this 
group of diseases, particularly 
with regard to morbidity, but 
its importance is being ignored 
and neglected. This chapter 
provides a summary of the 
current challenges facing asthma 
management worldwide and 
suggests several approaches 
addressing these issues. 
15. Neil Pearce, Javier Mallol 
Asthma is a global concern
Asthma has become an issue of international 
development. The asthma epidemic experienced 
by developed nations over the last 30 years is 
now hitting developing countries in a big way 
as they become more urbanised. Whilst it is true 
that communicable diseases such as malaria are 
still a major health problem for many developing 
countries, NCDs including asthma, allergic 
rhinitis, and eczema are now emerging as serious 
additional problems in these countries and 
authorities believe that they will be responsible 
for tomorrow’s pandemics. The majority of people 
with these conditions live in the developing 
world, and in some of those countries asthma has 
become more common than in some western 
countries.
Asthma is one of the 
significant NCDs
Asthma is now recognised as one of the 
most important NCDs in all regions of the world, 
affecting people in non-affluent as well as affluent 
countries. NCDs now outstrip communicable 
diseases as the leading causes of death in the 
world - 60% among people of all ages, most 
(80%) of these deaths occurring in non-affluent 
countries. Chronic respiratory diseases (CRDs) 
cause 15% of the world’s deaths, and many of 
these have their origins in childhood influences 
including asthma, which may be aggravated by 
tobacco use in pregnancy, exposure to second 
hand smoke in childhood, and taking up smoking 
in adolescent or adult years.  The burden and 
suffering caused by CRDs has been identified by 
the World Health Organization (WHO) as a priority 
issue. 
Asthma is an important 
NCD in all regions of the 
world, affecting people 
in non-affluent as well as 
affluent countries.
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Economic prosperity will be 
helped by treating asthma 
well….
The GBD found that asthma affects 
approximately 334 million people worldwide, 
causing an estimated 345,736 deaths annually 
(1 in 150 deaths worldwide). Around 22 million 
disability-adjusted life years (DALYs) are lost 
annually, and children with untreated asthma 
miss much of their primary school education, 
resulting in reduced educational opportunities 
and increased time off work for the parents/
guardians which then impacts on the economy 
through loss of productivity. People with asthma 
are less able to work or look after their families, 
which causes huge financial and emotional 
stress. Emergency visits, hospitalisation, and 
inappropriate treatments are a great financial 
drain on struggling health systems.
….especially in non-affluent 
countries
The burden of severe asthma symptoms 
(frequent attacks, waking at night, or breathing 
difficulty affecting speech) disproportionately falls 
among children with wheeze in low- and middle-
income countries.  These children especially need 
access to affordable asthma medicines to help 
reduce attacks and relieve symptoms.
More asthma research is 
needed
Asthma research is decades behind 
cardiovascular research, and needs further 
investment. A key challenge now is to identify 
modifiable environmental risk factors suitable 
for public health interventions which have the 
NCD priority actions will help 
asthma
Asthma symptoms will be helped by two 
of the five priority interventions for the NCD 
crisis - tobacco control and access to essential 
medicines. The reduction in obesity that will be 
achieved through a third priority of improved 
diets and physical activity is likely to be beneficial 
as a relationship between obesity and asthma is 
becoming more evident.
Asthma surveillance needs  
to be extended
We know that asthma has become a serious 
global health issue because health researchers 
(paediatricians, respiratory physicians, and 
epidemiologists) in 306 centres in 105 countries, 
wanting to estimate how large the problem was for 
children in their locality, joined the International 
Study of Asthma and Allergies in Childhood 
(ISAAC) research programme; it was found 
that asthma affects about one in seven of the 
world’s children. Through that information from 
ISAAC (children) and the European Community 
Respiratory Health Survey (ECRHS) (adults), and 
with the recent estimates from the Global Burden 
of Disease Study (GBD), we now know that asthma 
is an important NCD.  The WHO has resolved 
that there needs to be “better surveillance to 
map the magnitude of CRDs and analyse their 
determinants with particular reference to poor 
and disadvantaged populations and to monitor 
future trends”.  Thus surveillance of asthma needs 
to continue using simple instruments which can 
be widely used around the world and repeated at 
regular intervals, such as those used in ISAAC and 
including younger age groups, such as preschool 
children.
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ability to reduce the morbidity and severity of 
this increasing global problem. An important 
emerging problem is asthma or recurrent 
wheeze in infants, which was found, in a large 
international multi-centre study in 2008, to be 
highly prevalent and associated with greater 
severity in developing countries (see Chapter 5).
Universal access to quality-
assured and affordable 
asthma drugs 
Universal access to good-quality affordable 
drugs for NCDs is an important issue. For 
everyone with asthma, access to affordable 
medicines is needed, appropriate to the 
severity of their asthma – a β2 agonist reliever 
for all people with asthma, and an inhaled 
corticosteroid preventer for those with more 
frequent symptoms. These essential medicines, 
particularly inhaled corticosteroids, are not 
available or affordable to patients, or to the health 
service in many developing countries, and as a 
consequence people become disabled or die 
from asthma. Thus, asthma is a factor in increasing 
the poverty of individuals and countries, 
especially low- and middle-income countries. 
The International Union Against Tuberculosis and 
Lung Disease (The Union)  developed a process 
to provide access to quality-assured, affordably 
priced  asthma inhalers in resource-constrained 
settings (see Chapter 12). Such an approach must 
be continued. It must be added that quality-
assured and affordable holding chambers or 
spacers attached to inhalers are critical for the 
success of inhaled asthma therapy in childhood.
Organisation of health 
services for long term 
treatment 
In addition to the difficulty of accessing 
affordable essential medicines, the other main 
obstacle for management of NCDs, including 
asthma, is the lack of organisation of health 
services for long term management of patients 
with regular follow-up. Usually these diseases 
are treated only in an emergency. Training of 
health personnel and organisation of health 
services are needed. The Union has provided 
training material for health care workers; and, for 
regular monitoring and evaluation, an EpiData 
programme has been designed for registration 
and follow-up of patients.
Conclusion
Asthma is an NCD which causes a high burden 
of disease and economic impact throughout the 
world. The reasons for the increasing prevalence 
of asthma have not yet been clarified. Many 
people with asthma are not receiving effective 
treatment, often because quality-assured essential 
medicines are unavailable or unaffordable, or 
health care is not delivered well. There is a great 
deal that can be done to address all these issues, 
monitor their impact, and reduce the suffering of 
people with asthma in the world.
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Asthma is a major global health 
problem.
We know it is – world leaders please action 
all the recommendations in this report.
Asthma is one of the most significant 
NCDs globally and NCD priority actions 
will help prevent asthma. 
Keep asthma highlighted among NCDs.
Asthma monitoring needs to be 
ongoing.
Asthma needs to be studied in all countries, 
and the trends updated.
Asthma data need to be obtained for nearly 
half the world’s countries, which have not 
yet been surveyed.
Economic prosperity will be helped by 
correctly treating asthma, especially in 
non-affluent countries.
Measure the economic impacts of asthma, 
and the impact of adequate asthma 
management.
More asthma research is needed.
This includes research to identify the 
causes of asthma, especially in low- and 
middle-income countries; definition and 
management of asthma in infants and 
preschool children; and links between 
asthma in children and adolescents, and the 
development of COPD.
Universal access to quality-assured, 
affordable asthma medicines, delivery 
devices, and medical care is required.
Develop and implement policies to enable 
access to affordable good medical care 
and asthma medicines for all people with 
asthma in every country.
ACTIONS REQUIRED TO 
ENSURE ASTHMA BECOMES 
A GLOBAL PRIORITY:
Governments should include 
asthma in all their actions 
arising from the WHO Global 
Action Plan for the Prevention 
and Control of NCDs 2013-
2020, and the WHO NCD Global 
Monitoring Framework.
Key Recommendation
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ADF  Asthma Drug Facility
COPD  Chronic Obstructive Pulmonary Disease
CRDs  Chronic Respiratory Diseases
DALYs  Disability Adjusted Life Years
DOTS  Directly Observed Treatment Short-course
EAACI  The European Academy of Allergy and Clinical Immunology
ECRHS  European Community Respiratory Health Survey
ED  Emergency Department
EISL  Estudio Internacional de Sibilancias en Lactantes (International Study on Wheezing in Infants)
EML  Essential Medicines List
FIRS  Forum of International Respiratory Societies
GAN  Global Asthma Network
GBD  Global Burden of Disease Survey
GINA  Global Initiative on Asthma 
HFA  Hydrofluoroalkanes
HICs  High-Income Countries
ICS  Inhaled Corticosteroids
ISAAC  International Study of Asthma and Allergies in Childhood
LMICs  Low- and Middle-Income Countries
NCDs  Non-Communicable Diseases
NGO  Non-Governmental Organisation
NMRAs  National Medicine Regulatory Agencies
NRL  National Reimbursement List
pMDI  Pressurised Metered Dose Inhalers
RSV  Respiratory Syncytial Virus
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SMS  Short Message Service
The Union The International Union Against Tuberculosis and Lung Disease
TRIPS  Trade-Related aspects of Intellectual Property Rights
UN  United Nations
WHO  World Health Organization
YLD  Years Lived with Disability
YLL   Years of Life Lost 
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APPENDIX A: Tables and Figures
Chapter 2, Appendix Table 1: ISAAC world map data, symptoms of asthma.
Country  
(number of centres)
6-7 Year Age Group 13-14 Year Age Group
Current 
wheeze  
(%)
Asthma ever 
(%)
Symptoms 
of severe 
wheeze  
(%)
Symptoms of 
severe wheeze 
among current 
wheezers 
(%)
Current 
wheeze  
(%)
Current 
wheeze 
(video)  
(%)
Asthma ever 
(%)
Symptoms 
of severe 
wheeze  
(%)
Symptoms of 
severe wheeze 
among current 
wheezers 
(%)
Albania (1) 5.0 2.6 2.0 38.0 3.4 1.6 3.6 1.1 32.0
Algeria (1) 8.7 7.1 4.3 49.6
Argentina (4) 17.0 6.2 7.2 41.0 12.5 7.7 9.3 5.9 44.0
Australia (1) 20.0 26.0 8.4 40.0 30.6 15.0 37.3 12.1 38.1
Austria (1) 7.4 4.2 2.5 33.0 15.1 8.6 7.0 6.7 44.7
Barbados (1) 20.0 21.0 7.2 37.0 20.8 14.0 24.7 9.8 47.0
Belgium (1) 7.5 6.0 2.9 39.0 8.3 8.5 3.4 39.9
Bolivia (1) 13.5 16.0 12.3 8.0 43.8
Brazil (20) 24.0 10.0 12.0 43.0 18.7 12.0 13.3 8.1 34.1
Bulgaria (1) 5.6 4.3 2.2 35.0 8.2 5.5 4.5 36.1
Cameroon (1) 5.7 6.0 4.3 47.3
Canada (1) 18.0 19.0 6.8 37.0 13.7 16.3 5.0 33.5
Channel Islands (2) 26.5 12.0 26.3 12.2 43.1
Chile (5) 18.0 11.0 6.1 32.0 15.3 15.0 15.1 6.1 32.0
China (4) 3.6 2.0 3.5 1.3 31.1
Colombia (3) 14.0 8.7 4.8 32.0 11.8 10.0 14.2 6.0 39.6
Congo (1) 19.9 9.4 13.4 53.2
Cook Islands (1) 10.6 14.8 5.4 38.3
Costa Rica (1) 38.0 28.0 20.0 49.0 27.3 23.2 16.0 50.5
Côte d'Ivoire (1) 19.3 11.6 12.0 61.9
Croatia (1) 9.7 3.9 2.9 30.0 8.4 4.6 5.2 3.1 35.7
Cuba (1) 32.0 39.0 19.0 61.0 17.8 13.0 30.9 10.3 58.2
Ecuador (2) 17.0 5.0 4.7 28.0 16.6 11.0 10.9 6.3 37.8
Egypt (1) 7.0 5.2 3.9 38.0
El Salvador (1) 19.0 30.0 6.2 28.0 30.8 24.0 10.0 30.3
Estonia (1) 9.6 4.1 2.9 27.0 9.3 2.2 4.8 3.2 30.2
Ethiopia (1) 9.1 2.3 8.2 63.8
Fiji (1) 10.4 16.0 13.6 6.6 63.2
Finland (1) 19.0 3.3 7.7 5.1 25.2
France1 (5) 8.1 9.3 3.0 37.1 13.5 8.3 12.6 5.7 41.1
Gabon (1) 10.2 11.0 5.9 44.1
Georgia (1) 6.9 3.3 3.3 48.0 5.1 3.3 2.3 44.8
Germany (1) 13.0 4.6 5.2 39.0 17.5 6.8 8.0 9.6 50.8
Greece (1) 7.9 9.8 2.4 28.0
Honduras (1) 19.0 15.0 9.2 47.0 22.0 18.3 7.6 33.1
Hong Kong (1) 9.4 7.9 3.1 26.0 8.6 6.2 10.1 3.1 33.0
Hungary (2) 6.6 4.9 2.2 32.0 5.8 3.3 7.8 2.6 37.3
India (18) 5.3 4.1 2.8 40.0 5.8 4.7 5.1 3.4 47.8
Indonesia (3) 2.8 4.8 1.1 38.0 5.1 4.5 10.8 2.1 40.5
Iran (4) 9.7 4.0 4.7 38.0 10.8 3.7 3.4 5.9 43.5
Isle of Man (1) 14.0 21.0 6.9 47.0 31.2 28.6 12.4 36.4
Italy (13) 7.4 8.8 2.2 27.0 8.1 11.4 3.3 38.2
Japan (2) 18.0 23.0 3.3 17.0 10.0 14.9 3.4 33.3
Jordan (1) 17.0 10.0 10.0 61.0 12.3 6.8 7.6 7.8 62.6
Kenya (2) 15.8 11.0 14.5 11.3 66.8
Kingdom of Tonga (1) 16.2 11.0 12.5 7.9 48.4
Kuwait (1) 7.6 8.4 14.0 6.8 63.8
Kyrgyzstan (3) 5.8 1.2 4.1 69.0 7.8 2.8 2.5 6.1 72.8
Latvia (1) 10.5 3.1 7.2 3.9 30.4
Lebanon1 (1) 14.4 4.9 11.6 10.8 58.5
Lithuania (3) 5.4 2.0 1.4 26.0 7.3 6.1 2.5 1.8 24.4
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Symptoms of severe wheeze: Respondents with current wheeze who had 4 or more attacks of wheeze in the past year, or had 1 or 
more nights per week sleep disturbance from wheeze in the past year, or had wheeze affecting speech in the past year.
1 Phase One data
Country  
(number of centres)
6-7 Year Age Group 13-14 Year Age Group
Current 
wheeze  
(%)
Asthma ever 
(%)
Symptoms 
of severe 
wheeze  
(%)
Symptoms of 
severe wheeze 
among current 
wheezers 
(%)
Current 
wheeze  
(%)
Current 
wheeze 
(video)  
(%)
Asthma ever 
(%)
Symptoms 
of severe 
wheeze  
(%)
Symptoms of 
severe wheeze 
among current 
wheezers 
(%)
Malaysia (3) 5.8 11.0 1.7 25.0 8.9 4.9 12.0 3.3 32.2
Malta (1) 15.0 15.0 4.2 25.0 14.6 14.1 5.4 33.6
Mexico (10) 8.0 5.9 3.3 38.0 8.7 7.2 6.9 4.3 41.8
Morocco (4) 9.0 10.0 13.3 4.9 52.4
Netherlands (1) 12.2 13.0 5.3 43.0
New Zealand (5) 22.0 30.0 9.8 44.0 26.7 11.0 32.4 10.9 38.7
Nicaragua (1) 17.0 17.0 10.0 55.0 13.8 15.2 8.9 55.8
Nigeria (1) 5.6 3.3 6.7 57.0 13.0 10.0 11.7 11.9 64.2
Niue (1) 17.0 28.0 4.3 25.0 12.7 30.4 1.3 10.0
Nouvelle Calédonie (1) 8.2 6.9 12.5 3.6 43.9
Pakistan (2) 6.4 4.8 3.5 44.0 10.7 6.0 6.6 6.6 53.4
Palestine (2) 9.5 8.2 5.2 51.0 8.6 6.0 4.1 46.6
Panamá (1) 23.0 20.0 9.7 36.0 22.9 20.5 9.4 35.1
Paraguay (1) 20.9 11.0 12.8 10.8 51.8
Peru (1) 19.6 16.0 33.1 8.8 37.9
Philippines (1) 8.4 13.0 20.9 3.7 44.3
Poland (2) 14.0 5.8 6.0 43.0 10.2 6.1 5.3 41.3
Polynésie Française (1) 11.3 15.9 4.6 39.7
Portugal (5) 12.0 9.6 5.7 46.0 11.8 7.3 14.7 4.9 40.6
Rép de Guinée (1) 18.6 10.3 9.6 49.8
Rép Dém Congo (1) 7.5 10.2 3.3 41.6
Rep Ireland (1) 26.7 21.5 9.5 33.3
Rep Macedonia (1) 8.8 1.7 2.5 28.6
Reunion Island (1) 21.5 19.1 7.5 35.1
Romania (1) 22.7 8.9 9.0 39.9
Russia (1) 11.0 2.5 3.2 28.0 11.2 3.9 3.3 29.8
Samoa (1) 5.8 5.1 14.1 4.6 63.6
Serbia and Montenegro (5) 11.0 6.3 2.7 23.0 9.5 3.3 5.6 2.7 27.9
Singapore (1) 10.0 16.0 2.6 25.0 11.4 11.0 26.5 4.7 37.2
South Africa (2) 13.0 3.5 11.0 51.0 19.2 11.0 10.7 13.2 45.8
South Korea (2) 5.8 9.3 2.3 34.0 8.7 5.6 5.4 4.9 53.5
Spain (11) 10.0 11.0 3.6 33.0 10.6 7.3 13.9 4.7 40.8
Sri Lanka (1) 28.0 11.0 13.0 47.0 23.0 8.8 11.7 11.9 49.8
Sudan (1) 12.5 15.5 9.5 58.2
Sultanate of Oman (1) 8.4 11.0 5.1 60.0 8.4 8.1 19.9 5.3 62.3
Sweden (1) 10.0 9.3 4.2 39.0 9.7 3.7 12.0 3.4 31.7
Syrian Arab Republic (3) 5.2 4.2 2.9 45.0 5.2 5.1 5.1 3.6 41.9
Taiwan (2) 8.9 14.0 2.3 23.0 6.2 6.1 15.4 2.3 31.8
Thailand (6) 11.0 9.8 4.8 36.0 10.3 6.0 12.0 5.9 49.1
Togo (1) 16.8 10.1 9.9 41.7
Tokelau (1) 19.7 7.6 34.8 13.6 69.2
Trinidad and Tobago (2) 13.2 8.9 13.0 9.2 51.4
Tunisia (2) 14.3 9.3 9.2 45.5
Ukraine (2) 10.0 4.4 3.2 22.0 14.5 4.5 4.1 22.5
United Kingdom (6) 21.0 27.0 11.0 50.0 24.7 10.0 25.1 10.5 40.1
Uruguay (2) 23.0 9.8 9.0 40.0 16.4 10.0 17.0 8.1 48.9
USA (3) 22.1 13.0 17.4 11.5 48.8
Uzbekistan1 (2) 9.2 1.3 1.7 2.5 25.5
Venezuela (1) 20.0 29.0 12.0 55.0 15.4 29.7 9.7 51.6
Vietnam (1) 18.0 4.5 4.8 27.0 29.5 3.6 5.0 9.3 31.6
Global Totals 11.5 9.4 4.9 38.5 14.1 8.6 12.6 6.8 43.2
Sources: ISAAC Steering Committee. European Respiratory Journal 1998; Lai et al. Thorax 2009.  81
Chapter 9, Appendix Table 2: 
National asthma 
guidelines 
in countries 
responding to the 
Global Asthma 
Network survey, 
2013.
CountryName 1 2 3 4 5 6
Australia Yes15 Yes1 Yes2
Austria Yes16
Belgium
Canada Yes15
Channel Islands Yes2
Croatia Yes
Denmark
France Yes Yes14,16 Yes17 Yes1
French Polynesia Yes17
Germany Yes17
Greece Yes Yes1
Hong Kong Yes17 Yes1
Hungary Yes17
Ireland Yes17 Yes1
Italy Yes Yes15,16 Yes17 Yes1
Japan Yes14,16
Korea, South Yes17
Kuwait Yes1
Malta Yes1
Netherlands Yes16
New Caledonia Yes17
New Zealand Yes14,15,16 Yes17 Yes1 Yes2,3
Oman Yes15
Poland Yes17
Portugal Yes15,16
Reunion Island Yes17
Saudi Arabia Yes15
Singapore Yes17 Yes  1
Spain Yes Yes15,16 Yes14 Yes17
United Arab Emirates Yes17, 12
United Kingdom Yes15
United States Yes15
Albania Yes15 Yes1
Algeria Yes16,17
Argentina Yes16 Yes1
Armenia Yes1
Benin Yes Yes8
Bolivia Yes17 Yes1
Bosnia and Herzegovina Yes16,17 Yes2,4
Brasil Yes Yes15 Yes17 Yes1 Yes3
Bulgaria Yes Yes1
Burkina Faso Yes17
Cameroon Yes1
Chile Yes
China Yes17 Yes16 Yes1
Colombia Yes16 Yes17
Congo Dem Rep Yes
Costa Rica Yes1
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KEY TO TABLE
1. Will use WHO Guidelines
2. National guidelines 
with no pharmaceutical 
company involvement
3. National guidelines with  
pharmaceutical company 
involvement 
4. National guidelines with  
pharmaceutical company 
involvement not specified
5. Pharmaceutical company 
sponsored International 
guidelines 
6. International guidelines 
with no pharmaceutical 
company involvement
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1 Global Initiative for Asthma (GINA) 
guidelines
2 British Thoracic Society (BTS Sign) 
guidelines
3 National Asthma Education and 
Prevention Program (NAEPP) 
guidelines
4 World Health Organization 
(WHO) Package of Essential 
Noncommunicable (PEN) Disease 
Interventions for Primary Health Care 
in Low-resource Settings
5 WHO Practical approach to Lung 
Health (PAL) 
6 South African guidelines
7 International consensus on (ICON) 
pediatric asthma
8 The Union guidelines
9 Starship Auckland Children’s Hospital 
guidelines
10 Printing and dissemination
11 Submitted
12 Partial funding
13 In progress
14 Adult
15 Both ages
16 Child
17 Age unspecified
CountryName 1 2 3 4 5 6
Ecuador Yes15
Egypt Yes17 Yes1
El Salvador Yes8
Ethiopia Yes Yes15
Gambia Yes1
Georgia Yes17
Ghana Yes Yes17
India Yes Yes16 Yes17 Yes17 Yes1 Yes2
Indonesia Yes17
Iran Yes Yes17
Jordan Yes17
Kenya Yes Yes15
Kosovo Yes1
Latvia Yes1
Libya Yes
Macedonia Yes1 Yes7
Malawi Yes17
Mali Yes
Mexico Yes Yes16 Yes15 Yes16 Yes1 Yes3
Nicaragua Yes17
Nigeria Yes17 Yes17 Yes1 Yes6
Niue Yes9
Pakistan Yes1
Palestine Yes Yes15,17
Peru Yes15,16 Yes3,4,5
Philippines Yes10,14,16
Romania Yes1
Russia Yes Yes16,17 Yes16
Samoa Yes Yes9
Senegal Yes1
Serbia Yes15,16 Yes1
South Africa Yes14,16
Sri Lanka Yes1
Sudan Yes Yes8
Syrian Arab Republic Yes Yes1 Yes4,5
Taiwan Yes Yes15 Yes17
Thailand Yes Yes15 Yes1 Yes3
Togo Yes
Tokelau Yes
Tonga Yes17 Yes2
Tunisia Yes5
Turkey Yes14
Tuvalu Yes
Uganda Yes1
Uruguay Yes17
Vanuatu
Vietnam Yes Yes1
Zambia Yes17, 11 Yes1 Yes2
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Chapter 3, Appendix Figure 2: 
Asthma admission rates for 
European countries, age 5-14 
v 45+ years.
Source: WHO Hospital Morbidity Database. 
Accessed November 2013.
Source: WHO Hospital Morbidity Database. 
Accessed November 2013.
Chapter 3, Appendix Figure 1: 
Asthma admission rates 
for European countries, 
age 5-9 v 10-14 years.
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Chapter 3, Appendix Figure 3: 
Asthma admission rates for 
European countries, age 
20-44 v 45+ years.
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Chapter 8, Appendix Figure 4: 
National asthma 
strategies for 
children in countries 
responding to the 
Global Asthma 
Network survey, 2013.
Chapter 8, Appendix Figure 5:  
National asthma 
strategies for adults in 
countries responding 
to the Global Asthma 
Network survey, 2013.
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 No asthma strategy
 Has asthma strategy
 Unknown
 Not answered
 No response
 Not surveyed
 No asthma strategy
 Has asthma strategy
 Unknown
 Not answered
 No response
 Not surveyed
Q1.  Did you know that WHO has recently released guidelines for the management of asthma for children and adults?
Q2.  If Yes to Q1: Do you have a copy of the WHO guidelines?
Q3.  If No to Q2: Are you interested in having a copy of these guidelines for your use? (Link below)
  apps.who.int/iris/bitstream/10665/76173/1/9789241548397_eng.pdf                               
Q4.  Does your country intend to use the WHO guidelines for the management of asthma in children and adults?
Q5.  Do you have other guidelines that you use?
Q6.  If Yes to Q5: Would you send us a copy of your guidelines for children and adults to put on the Global Asthma Network  
 website as a resource?
Q7.  Does your centre or country have any short courses for asthma?
Chapter 9, Appendix Figure 6:  
Questions asked in the Global Asthma Network asthma guidelines survey 2013.
47%  
15%
 
30% 
8%
 
Breakdown of national asthma management guidelines (countries)  
Non-pharmaceutical industry 
sponsored guidelines
Pharmaceutical industry 
sponsored guidelines
Pharmaceutical industry 
sponsorship not specified
Both pharmaceutical and non-
pharmaceutical industry sponsored 
guidelines
Chapter 9, Appendix Figure 7: 
Pharmaceutical industry 
involvement in National 
Asthma Guidelines in 
countries responding to 
the Global Asthma Network 
survey, 2013.
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Silvarrey Varela 
Madrid, Professor Gloria García-
Hernández 
Málaga, Dr Julia Wärnberg 
San sebastián, Professor Eduardo 
G Pérez-Yarza 
Sevilla, Professor Manuel Praena-
Crespo 
Valencia, Professor Maria M. 
Morales Suárez-Varela
United Kingdom
Birmingham, Dr Adel H Mansur
Vatican City
Vatican City, MD Alessandro 
Fiocchi
 91
The Global Asthma Network (GAN) Steering Group would like to 
thank The Union for its generous support of the Global Asthma 
Reports 2011 and 2014, and all the activities of GAN to date. We also 
appreciate the support of the University of Auckland, which has 
provided facilities for GAN.
We would like to thank all of the authors who contributed to the 
chapters, and all of those around the world who collected data 
for this second Global Asthma Report. In particular we would 
like to acknowledge Eamon Ellwood, Website Manager, for the 
development and production of the report. The editing group were 
Innes Asher, Philippa Ellwood, Karen Bissell, David Strachan, Neil 
Pearce, Janet McAllister and Catherine Gilchrist.
We also acknowledge the enormously valuable contributions of our 
colleagues, participants and funders of ISAAC and The Union which 
underpin our work and this report.
Photographs were provided by Matthieu Zellweger on location in 
Thailand (Bangkok), Vietnam (Ho-Chi-Minh City),  and India (New 
Delhi), enabled by Professor Pakit Vichyanand (Thailand), Associate 
Professor Lan Thi Tuyet Lee (Vietnam), and Professor S K Sharma 
and Dr Ragesh R Nair (India). Matthieu Zellweger is represented and 
distributed by Haytham Pictures, Paris.
The design of the Global Asthma Report 2014 was undertaken by 
Eamon Ellwood in Auckland based on the Global Asthma Report 
2011 designed by Gilles Vérant in Paris.
ACKNOWLEDGEMENTS
PHOTOGRAPHY:
Matthieu Zellweger: ©2014, Thailand: 
cover, pages 1, 7, 14-15, 27, 28, 33, 35, 38, 
42-43, 48, 53, 58, 62, 65, 66-67; ©2014, 
Vietnam: pages 10, 12, 36, 39, 57; ©2014, 
India: pages 22, 27, 31, 47, 56, 60, 63, 64, 
68, 72, 73, 75.
Courtesy of the World Lung Foundation: 
Gary Hampton: ©2004, India: pages 4, 
61, ©2007, India: pages 5, 92-93; Jan van 
den Hombergh: ©2009, Ethiopia: page 
6; Damien Schumann: ©2009, South 
Africa: page 40; Jad Davenport: ©1997, 
Bangladesh: page 69.
Courtesy of the World Health 
Organization: 
Christopher Black: ©2008 France: page 
3. 2008
Courtesy of Worldbank: 
Scott Wallace: ©2009, Tanzania: page 25; 
Curt Carnemark: ©1992, Nepal: page 
41, ©2003, Bhutan: page 75; Tran Thi 
Hoa, ©2002, Vietnam: page 74; Shehzad 
Noorani: ©2002, Bangladesh: pages 76-77
Courtesy of Photoshare: Roobon, The 
Hunger Project, ©2004, Bangladesh: 
pages 8-9.
Courtesy of The New Zealand Asthma 
Foundation: ©2011, New Zealand: pages 
50,79,  ©2012, New Zealand: page 50.
Courtesy of stargazette.com: ©2007, 
United States of America: page 26.
Courtesy of UNESCO: Karel Prinsloo: 
©2013, Kenya: page 71.
APPENDIX D: ACKNOWLEDGEMENTS
DESIGN: 
Gilles Vérant, Paris
Eamon Ellwood, New Zealand
92 
 93
Global 
Asthma 
Network
Visit our website     www.globalasthmareport.org
ISBN: 978-0-473-29125-9
